Amgen (AMGN)

Company ID: 49 | CIK: 0000318154
10-Q view:
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
Segments are charted by their disclosed metrics (revenue, segment profit, etc.). Each line is a single segment. Reconciliation/corporate items are excluded. Major customers are shown as a percentage of revenue. Operational KPIs are grouped by metric concept; sub-metrics appear as separate lines.

Geographic Segments

No 10-Q data
No 10-K data

Business Unit / Product Segments

Major Customers (% of Revenue)

No 10-Q data

Operational KPIs

Employees by function (headcount)

Inventory balance (inventory_units)

No 10-K data

Accounts receivable past due (other)

No 10-K data

Advertising costs (other)

No 10-Q data

Available for stock repurchases (other)

No 10-K data

Basic weighted-average shares (other)

No 10-K data

BeOne ownership interest (other)

No 10-K data

BeiGene ownership interest (other)

No 10-K data

BeiGene ownership stake (other)

No 10-K data

Biosimilar molecules (other)

No 10-Q data

Capital expenditure guidance (other)

No 10-K data

Capital expenditures (other)

Cash and cash equivalents (other)

No 10-K data

Cash and marketable securities (other)

No 10-K data

Cash from operations (other)

No 10-K data

Cash, cash equivalents and marketable securities (other)

No 10-K data

Clinical trial patients enrolled (other)

No 10-K data

Commercial paper outstanding (other)

No 10-K data

Common shares outstanding (other)

No 10-K data

Common shares repurchased (other)

No 10-K data

Common stock outstanding (other)

No 10-K data

Common stock repurchased (other)

No 10-K data

Cost of sales percentage (other)

No 10-K data

Cost of sales ratio (other)

No 10-K data

Countries of operation (other)

No 10-Q data

Countries of presence (other)

No 10-Q data

Countries with commercial presence (other)

No 10-Q data

Countries with operations (other)

No 10-Q data

Countries with presence (other)

No 10-Q data

Countries with staff (other)

No 10-Q data

Country product launches (other)

No 10-Q data

Dialysis patient population growth (other)

No 10-K data

Diluted earnings per share (other)

No 10-K data

Diluted shares (other)

No 10-K data

Diluted weighted-average shares (other)

No 10-K data

Dividend per share (other)

No 10-K data

Dividends declared per share (other)

No 10-K data

Dividends paid (other)

No 10-K data

Dividends paid per share (other)

Durable response rate (other)

No 10-K data

ENBREL wholesaler stocking (other)

No 10-K data

EPOGEN dose utilization (other)

No 10-K data

EPOGEN dose utilization change (other)

No 10-K data

EPOGEN sales growth (other)

No 10-K data

EPOGEN sales growth rate (other)

No 10-K data

EPOGEN unit demand change (other)

No 10-K data

Earnings per share guidance (other)

No 10-K data

Effective tax rate (other)

No 10-K data

Effective tax rate excluding excise tax (other)

No 10-K data

Ethnic minority share (other)

No 10-Q data

Ethnic minority share of workforce (other)

No 10-Q data

FDA approvals (other)

No 10-Q data

FX benefit on international sales (other)

No 10-K data

Facilities footprint reduction (other)

No 10-K data

Foreign currency contracts outstanding (other)

No 10-K data

Foreign currency forward notional (other)

No 10-K data

Foreign currency forwards (other)

No 10-K data

Foreign currency hedge notional (other)

No 10-K data

Foreign currency options (other)

No 10-K data

Healthcare reform revenue impact (other)

No 10-K data

Holders of record (other)

No 10-Q data

Horizon product sales (other)

No 10-K data

Interest rate swap notional (other)

No 10-K data

International product sales mix (other)

No 10-K data

International product sales share (other)

No 10-K data

International share of product sales (other)

No 10-K data

Later-stage pipeline molecules (other)

No 10-Q data

Long-term debt outstanding (other)

No 10-K data

Marketable securities (other)

No 10-K data

Medicare contractors covering Prolia (other)

No 10-K data

Medicines submitted (other)

No 10-Q data

Medicines with positive data (other)

No 10-Q data

Mega-site clinical trials (other)

NEUPOGEN off-label AIDS sales percentage (other)

No 10-K data

NEUPOGEN sales (other)

No 10-K data

NEUPOGEN sales growth (other)

No 10-K data

NEUPOGEN sales growth rate (other)

No 10-K data

Net cash provided by operating activities (other)

No 10-K data

Net selling price change (other)

No 10-K data

Neulasta Onpro penetration (other)

No 10-K data

Neulasta Onpro share (other)

No 10-Q data

Neulasta Onpro share of sales (other)

No 10-Q data

Nonvested restricted stock (other)

No 10-K data

Novartis cost recovery (other)

No 10-K data

Nplate U.S. government orders (other)

No 10-K data

Nplate US government orders (other)

No 10-K data

Number of Reportable Segments (other)

Objective response rate (other)

No 10-K data

Off-label AIDS sales share (other)

No 10-K data

Off-label NEUPOGEN sales (other)

No 10-Q data

Off-label NEUPOGEN usage (other)

No 10-K data

Off-label sales share (other)

No 10-Q data

Onpro kit share (other)

No 10-Q data

Operating cash flow (other)

No 10-K data

Operating income margin (other)

No 10-K data

Operating margin (other)

No 10-K data

Operating margin on product sales (other)

No 10-K data

Other brands volume growth (other)

No 10-K data

Outstanding debt (other)

No 10-K data

Past-due trade receivables (other)

No 10-K data

Patient population growth (other)

No 10-Q data

Phase 3 pipeline programs (other)

No 10-Q data

Phase 3 programs (other)

No 10-Q data

Principal product sales concentration (other)

No 10-K data

Principal product sales share (other)

No 10-K data

Principal products concentration (other)

No 10-K data

Principal products sales share (other)

No 10-K data

Principal products share (other)

No 10-K data

Principal products share of sales (other)

No 10-K data

Product sales (other)

No 10-K data

Product sales growth (other)

No 10-K data

Product sales growth rate (other)

No 10-K data

Product sales share of revenues (other)

No 10-K data

Product sales volume growth (other)

Prolia inventory capitalized (other)

No 10-K data

Quarterly dividend declared (other)

No 10-K data

Quarterly dividend per share (other)

No 10-K data

R&D expense (other)

No 10-Q data

R&D expense ratio (other)

No 10-K data

Remaining buyback authorization (other)

No 10-K data

Remaining repurchase authorization (other)

No 10-K data

Remaining share repurchase authorization (other)

No 10-K data

Remaining stock repurchase authorization (other)

No 10-K data

Repatriation tax obligation (other)

No 10-K data

Repurchase authority remaining (other)

No 10-K data

Repurchase authorization remaining (other)

No 10-K data

Research and development expense growth rate (other)

No 10-K data

Research and development ratio (other)

No 10-K data

Restricted stock outstanding (other)

No 10-K data

Restructuring charges (other)

No 10-K data

Restructuring charges incurred (other)

No 10-K data

Restructuring costs incurred (other)

No 10-K data

Restructuring liability (other)

No 10-K data

Restructuring pre-tax charges estimate (other)

No 10-K data

Restructuring reserve (other)

No 10-K data

Restructuring reserves (other)

No 10-K data

Restructuring staff reduction target (other)

No 10-K data

Restructuring staff reductions (other)

No 10-Q data

SG&A expense ratio (other)

No 10-K data

Sales deductions (other)

No 10-Q data

Sales deductions rate (other)

No 10-Q data

Selling, general and administrative ratio (other)

No 10-K data

Share repurchase spend (other)

No 10-K data

Shares outstanding (other)

Shares repurchased (other)

Stock options outstanding (other)

Stock repurchase authorization (other)

No 10-K data

Stock repurchase authorization remaining (other)

No 10-K data

Stock repurchase cost (other)

No 10-K data

Stock repurchase expenditure (other)

No 10-K data

Stock repurchase program remaining (other)

No 10-K data

Stock repurchase spending (other)

No 10-K data

Stock repurchased (other)

No 10-K data

Stock repurchases (other)

Stock repurchases available (other)

No 10-K data

Stock shares repurchased (other)

No 10-K data

Tarlatamab median overall survival (other)

No 10-K data

Tarlatamab median progression-free survival (other)

No 10-K data

Tarlatamab objective response rate (other)

No 10-K data

Total Debt (other)

No 10-K data

Total carrying value of debt (other)

No 10-K data

Total debt (other)

No 10-K data

Total debt outstanding (other)

No 10-K data

Total product sales growth (other)

No 10-K data

Transformation savings (other)

No 10-K data

Transformation savings realized (other)

U.S. government product orders (other)

No 10-K data

Volume growth (other)

No 10-K data

Weighted average diluted shares (other)

No 10-K data

Weighted average shares (other)

No 10-K data

Weighted-average diluted shares (other)

No 10-K data

Weighted-average lease discount rate (other)

No 10-K data

Weighted-average lease term (other)

No 10-K data

Weighted-average shares (other)

No 10-K data

Wholesaler customer concentration (other)

No 10-Q data

Wholesaler inventory level (other)

No 10-Q data

Wholesaler inventory levels (other)

No 10-Q data

Wholesaler inventory weeks (other)

No 10-Q data

Wholesaler revenue concentration (other)

No 10-Q data

Wholesaler sales concentration (other)

No 10-Q data

Women share of workforce (other)

No 10-Q data

Women workforce share (other)

No 10-Q data

Workforce diversity (other)

No 10-Q data

Wyeth profit share expense (other)

No 10-K data

Wyeth share ownership (other)

No 10-K data

Year 2000 expenditures expected (other)

No 10-K data

Year 2000 expenditures incurred (other)

No 10-K data

Year 2000 program expenditures (other)

No 10-K data

Year 2000 program spend (other)

No 10-K data

Year 2000 program total cost (other)

No 10-K data

Clinical trial patients enrolled (patients)

No 10-K data

Buildings (properties)

No 10-Q data
Human capital disclosures. Workforce totals and demographics are point-in-time. Flow metrics use the year-to-date period for 10-Q and full year for 10-K. Workforce actions (RIFs, restructurings, acquisition-related changes) are listed in the table at the bottom.

Workforce Totals

No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data

Demographics

No 10-Q data
No 10-Q data
No 10-Q data

Workforce Breakdowns

No 10-Q data
No 10-Q data
No 10-Q data

HCM Metrics — Point-in-Time

No point-in-time HCM metrics found.

HCM Metrics — Flow (Annual / YTD)

No flow HCM metrics found.

Workforce Actions

Period EndTypeStatusAffected% WorkforceAnnouncedExpected CompletionGeographySegment / FunctionChargeSourceNote
2024-12-31restructuringcompleted2023-01-012023-12-31GlobalVariousMD&A
f5-10k / Qwen3.6-27B-Q8_0		Restructuring plan initiated and substantially completed in 2023. Expenses related to cost-savings initiatives incurred in 2024.
2024-12-31acquisition_additioncompleted2023-10-062023-10-06GlobalHuman Therapeuticsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Horizon Therapeutics plc completed on October 6, 2023. Headcount added not explicitly quantified in filing.
2023-12-31restructuringcompleted20232023USD 267 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Plan initiated in the first quarter of 2023 to reallocate resources toward first-in-class medicines and improve the cost structure; substantially all activities were completed in 2023. Total charges of $267M comprised $186M separation costs (recorded in Other operating expenses) and $81M asset impairments and other charges. Number of employees affected not disclosed. Restructuring liability of $45M remained at December 31, 2023 after separation-cost payments.
2023-12-31acquisition_additioncompleted2023-10-062023-10-06GlobalUSD 167 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Horizon completed October 6, 2023 for approximately $27.8B total consideration; headcount acquired not disclosed. Q4 2023 acquisition costs of approximately $487M included $167M for share-based payments to settle non-vested equity awards attributable to post-combination services plus severance and other employee-related expenses. 1.7M replacement RSUs were issued to Horizon RSU holders with original vesting terms.
2023-12-31divestiture_reductioncompleted20232023other
f5-10k / GLM-5.3-flash-HTML		Divestiture of the Bergamo subsidiary completed in the second quarter of 2023; disclosed only via product sales footnotes. No workforce details, employee counts, or divestiture-related charges were disclosed in the filing.
2023-12-31restructuringcompleted2023-03-312023-12-31GlobalCompany-wideUSD 267 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Plan initiated in Q1 2023 to improve cost structure and reallocate resources; substantially all activities completed in 2023. Charge comprises $186M separation costs and $81M asset impairments/other. Restructuring liability of $45M remained at year-end. Employees affected not disclosed.
2023-12-31acquisition_additioncompleted2023-10-062023-10-06GlobalRare disease / InflammationUSD 487 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Horizon Therapeutics acquired for $27.8B total consideration; headcount added not disclosed. $487M of acquisition costs incurred in Q4 2023, including $167M for settling non-vested equity awards, severance and other employee-related expenses, and $320M transaction costs.
2023-12-31divestiture_reductioncompleted2023-06-302023-06-30TurkeyOtherother
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Bergamo subsidiary divested in Q2 2023; headcount removed not disclosed. Disclosed only via reference to sales prior to divestiture.
2023-12-31restructuringcompleted2023-03-312023-12-31GlobalVariousUSD 267 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Initiated in Q1 2023 to enhance innovation and improve cost structure. Substantially all activities completed in 2023. Total charges $267 million ($186 million separation costs, $81 million asset impairments/other). Employee count not explicitly disclosed in footnote.
2023-12-31acquisition_additioncompleted2023-10-062023-10-06GlobalRare Diseasebusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Horizon Therapeutics plc completed on October 6, 2023. Headcount added not explicitly quantified in the filing.
2023-12-31restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressCost of Sales [Member] / Other Restructuring [Member]USD 36,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressCost of Sales [Member]USD 36,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressResearch and Development Expense [Member] / Other Restructuring [Member]USD 29,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressResearch and Development Expense [Member]USD 29,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Other Restructuring [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressOther [Member] / Employee Severance [Member]USD 186,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressOther [Member] / Other Restructuring [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressOther [Member]USD 189,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressEmployee Severance [Member]USD 186,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressOther Restructuring [Member]USD 81,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressUSD 267,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-09-30restructuringin_progress2023-01-01USD 252 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan initiated Q1 2023 to reallocate resources toward first-in-class medicines and improve cost structure; includes staff reductions and asset impairments from geographic footprint rationalization. Company expects $250-$350 million of pretax charges in 2023; $252 million recorded in the nine months ended September 30, 2023 ($182 million separation costs, $70 million asset impairments and other charges). No employee counts disclosed. Restructuring liability of $54 million as of September 30, 2023, included in Accrued liabilities.
2023-09-30acquisition_additioncompleted2023-10-06USD 27,800 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Amgen completed acquisition of Horizon Therapeutics plc on October 6, 2023 for $116.50 per share in cash, transaction equity value approximately $27.8 billion. No headcount figures disclosed; Horizon adds more than 30 contract manufacturing organizations per risk factors. Horizon results to be consolidated beginning Q4 2023.
2023-09-30restructuringin_progressrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan initiated in Q1 2023 (exact announcement date not disclosed); includes separation and other headcount-related costs for staff reductions plus asset impairments. Company expects $250M to $350M of pretax charges in 2023. Charges recorded: $31M in Q3 2023 and $252M for the nine months ended 2023-09-30. Restructuring liability was $54M at 2023-09-30. Number of employees affected not disclosed.
2023-09-30acquisition_additioncompleted2023-10-062023-10-06Inflammation / rare and autoimmune diseases portfoliosubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Horizon Therapeutics plc completed 2023-10-06, after quarter end, for $116.50 per share (~$27.8B equity value); filing discloses completion date only, not a prior announcement date. Headcount added not disclosed; initial purchase accounting incomplete. Results of operations to be consolidated beginning Q4 2023.
2023-09-30restructuringin_progress2023-03-31USD 252 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Initiated in Q1 2023 to enhance innovation and improve cost structure. Includes separation costs and asset impairments. Expected total pretax charges of $250M-$350M in 2023. YTD charges of $252M recorded.
2023-09-30restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressCost of Sales [Member] / Other Restructuring [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressCost of Sales [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressResearch and Development Expense [Member] / Other Restructuring [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressResearch and Development Expense [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Other Restructuring [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressOther [Member] / Employee Severance [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressOther [Member] / Other Restructuring [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressOther [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressEmployee Severance [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressOther Restructuring [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressUSD 31,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progress2023-01-01USD 221 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan initiated in Q1 2023 to reallocate resources and improve cost structure; includes staff reductions and asset-related charges from geographic footprint rationalization. Company expects $300-$400 million of pretax charges in 2023; $221 million recorded in the six months ended June 30, 2023 ($42 million in Q2). Restructuring liability of $82 million as of June 30, 2023. No employee counts disclosed.
2023-06-30restructuringin_progress2023-03-312023-12-31USD 221 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan initiated in Q1 2023 (exact announcement date not disclosed; date shown is quarter-end of initiation). No employee count disclosed. Six-month 2023 charges of $221M comprise $166M separation costs and $55M asset impairments/other; Q2 charges were $42M. Company estimates $300M–$400M of pretax charges in 2023 covering staff reductions and asset-related charges from geographic footprint rationalization. Restructuring liability was $82M at 2023-06-30. Charges recorded across Cost of sales, R&D, and Other operating expense lines.
2023-06-30restructuringin_progress2023-03-312023-12-31GlobalVariousUSD 350 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Initiated in Q1 2023 to enhance innovation and improve cost structure. Estimated total pretax charges of $300M-$400M in 2023, including separation costs and asset impairments. YTD charges of $221M recorded.
2023-06-30restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressCost of Sales [Member] / Other Restructuring [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressCost of Sales [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressResearch and Development Expense [Member] / Other Restructuring [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressResearch and Development Expense [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressOther [Member] / Employee Severance [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressOther [Member] / Other Restructuring [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressOther [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressEmployee Severance [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressOther Restructuring [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressUSD 42,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progress2023-01-012023-12-31USD 179 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring plan initiated in Q1 2023 to enhance innovation and improve cost structure; expected 2023 pretax charges of $300-400 million including headcount-related separation costs and asset-related charges from geographic footprint rationalization. Q1 charges: $141 million separation/headcount costs in Other operating expenses and $38 million asset-related charges primarily in Cost of sales; $132 million restructuring liability in Accrued liabilities at quarter-end. Employee count not disclosed.
2023-03-31restructuringin_progress2023-01-012023-12-31GlobalHuman therapeutics (company-wide)USD 350 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Estimated $300M–$400M pretax charges in 2023; midpoint shown. Q1 incurred $141M separation/headcount costs plus $38M asset-related charges; $132M restructuring liability accrued at quarter-end. No employee count disclosed.
2023-03-31restructuringin_progress2023-03-312023-12-31GlobalVariousUSD 300 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Initiated plan to enhance innovation and improve cost structure. Estimated total pretax charges $300M-$400M in 2023. Q1 incurred $141M separation/headcount costs and $38M asset-related charges. Employee count not disclosed.
2022-12-31acquisition_additioncompleted2022-08-032022-10-20United StatesInflammation (TAVNEOS added to portfolio)USD 106 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired all outstanding stock of ChemoCentryx for $52.00 per share, total consideration approximately $3.9 billion; merger agreement dated 2022-08-03 (per Exhibit 10.11.4) and completed 2022-10-20. Employee headcount added not disclosed. The $106 million of Q4 2022 acquisition-related costs comprised share-based payments for post-combination services, severance, and other transaction costs.
2022-12-31divestiture_reductioncompleted2022-11-022022-11-02TurkeyUSD 567 (millions)other
f5-10k / GLM-5.3-flash-HTML		Sold shares in Turkish subsidiary Gensenta İlaç Sanayi ve Ticaret A.Ş. to Eczacıbaşı for net cash proceeds of approximately $130 million; recognized a $567 million loss on divestiture, primarily from reclassification of $615 million of cumulative foreign currency translation losses. Employee headcount removed not disclosed; transaction not classified as discontinued operations.
2022-12-31acquisition_additionannounced2022-12-12Ireland (target headquartered in Dublin, Ireland)Rare, autoimmune and severe inflammatory diseasesItem_1_Business
f5-10k / GLM-5.3-flash-HTML		Transaction agreement to acquire all Horizon Therapeutics plc shares for $116.50 per share in cash, equity value approximately $27.8 billion; $28.5 billion bridge and term loan credit facilities arranged. Closing contingent on regulatory approvals including FTC review (Second Request received 2023-01-30). Employee headcount impact not disclosed.
2022-12-31acquisition_additioncompleted2022-08-032022-10-20United StatesInflammationbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired all outstanding stock of ChemoCentryx at $52.00/share; total consideration $3.9 billion ($3.8 billion net of cash acquired). Added TAVNEOS to the inflammation portfolio. Headcount added not disclosed; approximately $106 million of acquisition-related costs recorded in SG&A.
2022-12-31divestiture_reductioncompleted2022-11-022022-11-02TurkeyUSD 567 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sold shares in Turkish subsidiary Gensenta for net cash proceeds of approximately $130 million; loss on divestiture of $567 million, primarily reclassification of $615 million of cumulative FX translation losses from AOCI. Headcount removed not disclosed.
2022-12-31acquisition_additionannounced2022-12-12Ireland (global operations)Rare, autoimmune and severe inflammatory diseasesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire Horizon at $116.50/share, equity value approximately $27.8 billion; funded via $28.5 billion bridge and term loan credit agreements (undrawn at year-end). Closing contingent on regulatory and customary conditions; FTC Second Request received 2023-01-30. Headcount to be added not disclosed.
2022-09-30divestiture_reductioncompleted2022-06-282022-11-02TurkeyUSD 565 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Share purchase agreement with Eczabasi for the Gensenta subsidiary; $565M loss recorded in Other operating expenses, primarily cumulative foreign currency translation loss, not severance. No employee count disclosed.
2022-09-30acquisition_additioncompleted2022-10-202022-10-20subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Completed acquisition of ChemoCentryx at $52.00 per share, approximately $3.7B aggregate merger consideration; initial accounting incomplete and no headcount impact disclosed. Results begin in Q4 2022.
2022-06-30divestiture_reductionannounced2022-06-282022-09-30TurkeyGensenta İlaç Sanayi ve Ticaret A.Ş. subsidiaryUSD 560 (millions)other
f5-10q / GLM-5.3-flash-fp4-HTML		Share purchase agreement with Eczacıbaşı to sell all Amgen shares in Gensenta; expected close in Q3 2022 pending Turkish Competition Authority approval. $560 million loss recognized in Q2 2022, primarily from cumulative foreign currency translation loss. Employee headcount affected not disclosed.
2022-06-30divestiture_reductionin_progress2022-06-282022-09-30TurkeyGensenta İlaç Sanayi ve Ticaret A.Ş. (subsidiary)USD 560 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Share purchase agreement with Eczacıbaşı; $560M loss recognized in Other operating expenses, primarily from cumulative FX translation loss. No employee count disclosed; closing expected Q3 2022 subject to Turkish Competition Authority approval.
2022-06-30acquisition_additionannounced2022-08-042022-12-31United StatesChemoCentryx, Inc. — autoimmune/inflammatory therapeuticsUSD 4,000 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter announcement (subsequent event) of cash acquisition at $52.00/share, ~$4.0B total; expected close Q4 2022. No headcount disclosed.
2022-03-31acquisition_additioncompleted2021-10-19United StatesResearch and DevelopmentUSD 1,292 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Teneobio became a wholly owned subsidiary; no employee count disclosed. Charge shown is total consideration, not a workforce charge. Q1 2022 measurement-period adjustments added $22M to goodwill.
2021-12-31acquisition_additioncompleted2021-03-042021-04-16United StatesUSD 1,600 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of clinical-stage immuno-oncology company completed April 16, 2021 for approximately $1.6 billion cash net of cash acquired; accounted for as asset acquisition. No employee headcount disclosed. Merger agreement dated March 4, 2021.
2021-12-31acquisition_additioncompleted2021-07-272021-10-19United StatesUSD 1,303 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Business combination completed October 19, 2021: cash purchase price $994 million plus contingent consideration fair value $309 million (total consideration $1,303 million); milestone payments of up to $1.6 billion additional. No employee headcount disclosed. Merger agreement dated July 27, 2021.
2021-12-31acquisition_additioncompleted2021-03-042021-04-16United StatesOncology / R&DUSD 1,600 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Five Prime completed April 16, 2021 for approximately $1.6 billion net of cash acquired; no headcount added is disclosed. Consideration allocated to bemarituzumab IPR&D expensed as acquired IPR&D.
2021-12-31acquisition_additioncompleted2021-07-272021-10-19United StatesR&D / OncologyUSD 900 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Teneobio acquired October 19, 2021 for $994 million cash plus contingent consideration fair-valued at $309 million (up to $1.6 billion in milestones); no headcount added is disclosed. Accounting treated as a business combination.
2021-09-30acquisition_additionannounced2021-07-272021-10-19United StatesResearch and DevelopmentUSD 900 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Teneobio, Inc. acquisition closed 2021-10-19 for $900M upfront plus up to $1.6B contingent milestones; headcount added not disclosed. Merger agreement dated 2021-07-27. Initial purchase accounting incomplete as of filing.
2021-03-31acquisition_additioncompleted2021-04-162021-04-16United StatesResearch & Developmentsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Five Prime Therapeutics completed 2021-04-16 for ~$1.9 billion cash; headcount added not disclosed. MD&A notes an expected Q2 2021 R&D charge from the acquisition.
2020-12-31acquisition_additioncompleted2020-04JapanItem_1_Business
f5-10k / GLM-5.3-flash-HTML		Purchase of the remaining shares of the Amgen Astellas BioPharma K.K. joint venture from Astellas was completed in April 2020 (date shown is the disclosed completion month); the affiliate was renamed Amgen K.K. and became wholly owned. Filer states the purchase did not materially affect consolidated financial statements and does not quantify employees added.
2020-12-31acquisition_additioncompleted2020-04-302020-04-30JapanCommercialItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Completed purchase of remaining shares of Amgen Astellas BioPharma K.K. joint venture, now wholly owned Amgen K.K.; no headcount disclosed and filing states no material financial statement impact. Exact April 2020 day not specified.
2019-12-31restructuringcompletedUSD 47 (millions)MD&A
f5-10k / GLM-5.3-flash-HTML		FY2019 other operating expenses included $47 million in restructuring costs; no employee counts, program scope, or completion timeline disclosed. Status inferred as completed since the full charge was recognized within the fiscal year. No restructuring footnote with further detail appears in the filing.
2019-12-31acquisition_additioncompleted2019-08-252019-11-21GlobalInflammationUSD 13,400 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of worldwide rights to Otezla from Celgene for $13.4 billion cash; headcount added not disclosed. Otezla excluded from management's ICFR assessment (0.6% of total assets, 0.8% of revenues).
2019-12-31restructuringin_progressNot specifiedNot specifiedUSD 47 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		MD&A discloses $47 million of restructuring costs in 2019 within Other operating expenses; no employee-affected count, geography, or timeline provided in this filing.
2019-12-31otherannounced2020-01-02ChinaOncologyUSD 2,800 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Post-year-end 20.5% equity investment in BeiGene for ~$2.8 billion plus strategic collaboration; equity stake rather than headcount acquisition, no employee count disclosed.
2019-12-31restructuringcompleted2019GlobalVariousUSD 47 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Other operating expenses for 2019 included $47 million in restructuring costs. Employee count not disclosed.
2019-09-30acquisition_additioncompleted2019-07-152019-07-15DenmarkResearch and DevelopmentUSD 183 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of all outstanding stock of Nuevolution AB for $183 million cash; no employee count disclosed. Consideration allocated to $150M intangibles, $26M goodwill, $22M deferred tax liabilities, $29M other net assets.
2019-09-30acquisition_additionannounced2019-08-252019-12-31WorldwideHuman therapeuticsUSD 13,400 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire worldwide rights to Otezla (apremilast) and related assets/liabilities for $13.4 billion, funded with cash; expected to close by end of 2019. No employee count disclosed; closing contingent on FTC approval in connection with the BMS/Celgene merger.
2018-12-31restructuringcompleted20142018United States (Washington State and Colorado facility closures; Thousand Oaks, California headquarters and other locations)USD 12 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Transformation and process improvement restructuring plan initiated in 2014; included facility closures in Washington State and Colorado and consolidation of occupied buildings at the Thousand Oaks headquarters and other locations. Plan activities were completed in 2018. No employee count was disclosed. FY2018 restructuring charge was $12 million; cumulative through fiscal year-end: $548 million separation and other headcount-related costs plus $261 million net asset-related charges ($809 million total). Company also reported approximately $1.9 billion of realized transformation/process improvement savings since 2014.
2018-12-31acquisition_additioncompleted20182018business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		In Q1 2018, Amgen acquired the remaining 50% ownership interest in Kirin-Amgen, Inc. (K-A) from Kirin Holdings for $780 million in cash, making K-A a wholly owned subsidiary and consolidating its operations. The filing does not disclose the employee headcount added through the acquisition.
2018-12-31restructuringcompleted2014-01-012018-12-31United States (Washington State, Colorado, Thousand Oaks and other locations)Company-wideUSD 12 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Restructuring plan initiated in 2014; activities completed during 2018. FY2018 charge of $12M; cumulative costs to date $809M ($548M separation/headcount, $261M asset-related). Employees affected not disclosed.
2018-12-31acquisition_additioncompleted2018-03-312018-03-31GlobalCompany-widebusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired remaining 50% of Kirin-Amgen in Q1 2018, making it a wholly owned subsidiary; headcount added not disclosed. Announcement date shown as quarter-end placeholder (exact date not stated).
2018-12-31restructuringcompleted20142018-12-31GlobalVariousUSD 12 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Initiated in 2014; activities completed in 2018. $12 million incurred in 2018. Total cumulative costs $809 million.
2018-09-30restructuringin_progress2014-01-01United StatesCompany-wideUSD 798 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2014 restructuring plan: facility closures in Washington State and Colorado plus headquarters consolidation; estimated total pretax charges of $800-850 million, including $540-560 million separation/headcount costs and $260-290 million asset-related charges. Through September 30, 2018, $547 million separation costs and $251 million net asset-related charges incurred; charges in the current quarter and YTD were not significant and the remaining liability was not significant. No employee counts disclosed.
2018-09-30restructuringin_progress2014United States (Washington State, Colorado, Thousand Oaks, CA and other locations)Company-widerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2014 plan; no employee counts disclosed. Estimated $800M–$850M pretax charges ($540M–$560M separation/headcount, $260M–$290M asset-related). Through 2018-09-30 incurred $547M separation/headcount costs and $251M net asset charges; Q3 2018 charges and remaining liability not significant.
2018-09-30acquisition_additioncompleted2018-03-31GlobalHuman therapeutics (Kirin-Amgen, Inc. joint venture)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2018 acquisition of remaining 50% of Kirin-Amgen, Inc.; $780M cash paid. No headcount added disclosed; pro forma results not presented as immaterial.
2018-09-30restructuringin_progress2014GlobalVariousUSD 798 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Initiated in 2014. Total estimated pretax charges $800M-$850M. Incurred $798M through Sept 30, 2018. Includes separation costs and asset-related charges. No specific employee count disclosed for current period activity.
2018-06-30restructuringin_progress2014-01-01United StatesUSD 794 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2014 restructuring plan; cumulative pretax charges of $794 million incurred through June 30, 2018 against an estimated total of $800-$900 million, including $549 million separation/headcount costs and $245 million asset-related charges. Charges in the current quarter were not significant and no employee counts were disclosed.
2018-06-30restructuringin_progress2014United States (Washington State, Colorado facility closures; Thousand Oaks, CA headquarters consolidation)Company-widerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program initiated 2014 with estimated total pretax charges of $800M-$900M, including $540M-$600M separation/headcount costs and $260M-$300M asset-related charges. Cumulative through 2018-06-30: $549M separation/headcount costs and $245M net asset charges. Period charges and total restructuring liability were not significant; no employee count disclosed.
2018-06-30restructuringin_progress2014GlobalVariousUSD 794 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2014 restructuring plan to invest in innovation and improve cost structure. Includes facility closures in WA and CO, and HQ consolidation. Total pretax charges estimated $800M-$900M. $794M incurred to date ($549M separation/headcount, $245M asset-related). Charges in Q2 2018 were not significant.
2018-03-31restructuringin_progress2014-01-01United States (Washington State, Colorado, Thousand Oaks CA headquarters, other locations)USD 801 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2014 restructuring plan; total estimated pre-tax charges of $825-900 million, including $560-600 million separation/headcount-related costs and $265-300 million asset-related charges. Through March 31, 2018, $558 million separation costs and $243 million net asset-related charges incurred ($801 million total per MD&A). Charges in Q1 2018 were not significant; restructuring liability not significant as of March 31, 2018. Employee counts affected not disclosed.
2018-03-31restructuringin_progress2014GlobalVariousUSD 801 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Initiated in 2014. Total incurred costs as of March 31, 2018 were $801 million ($558 million separation/headcount-related, $243 million asset-related). Charges recorded in Q1 2018 were not significant.
2017-12-31restructuringin_progress20142018United States (facility closures in Washington and Colorado; consolidation of headquarters buildings in Thousand Oaks, California) with worldwide facility consolidationCompany-wideUSD 88 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year transformation plan initiated 2014; estimated total pre-tax charges of $825M-$900M, including $560M-$600M of separation and other headcount-related costs for staff reductions and $265M-$300M of asset-related charges. Cumulative charges through FY2017: $797M ($558M separation/headcount-related, $239M net asset-related). FY2017 restructuring costs of $88M per MD&A; the footnote liability roll-forward shows FY2017 expenses excluding non-cash charges of $79M ($72M separation costs, $7M other) with $31M of payments, leaving a $68M liability at year-end. Most remaining estimated costs expected in 2018. Number of employees affected by staff reductions not disclosed. Same action referenced in MD&A; extracted once from the more detailed footnote per deduplication rule.
2017-12-31restructuringin_progress20142018United StatesCompany-wideUSD 88 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2014 multi-year restructuring plan; $88M of restructuring costs incurred in FY2017 (footnote cash-expense table shows $79M excluding non-cash charges). Cumulative charges of $797M against an estimated $825M-$900M program total; most remaining costs expected in 2018. No employees-affected count disclosed; closures included facilities in Washington and Colorado and building consolidation in Thousand Oaks, CA.
2017-12-31acquisition_additionannounced2017-10-302018-03-31GlobalKirin-Amgen, Inc. joint ventureUSD 780 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire the remaining 50% of Kirin-Amgen, Inc. from Kirin for $780M plus contingent payments valued at approximately $30M; completed in Q1 2018, making K-A a wholly owned subsidiary. Charge shown is purchase consideration, not severance. No headcount added disclosed.
2017-12-31restructuringin_progress20142018-12-31GlobalVariousUSD 88 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Part of a multi-year transformation plan initiated in 2014. $88 million incurred in 2017. Total estimated pre-tax charges $825-$900 million. Most remaining costs expected in 2018.
2017-12-31restructuringin_progressUSD 79,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressEmployee Severance [Member]USD 72,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressOther Restructuring [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-09-30restructuringin_progress2014-01-01United States (Washington State, Colorado, Thousand Oaks CA headquarters and other locations)USD 800 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2014 restructuring plan: facility closures in Washington and Colorado plus headquarters consolidation; total estimated pre-tax charges of $800-$900 million, including $535-$585 million separation/headcount costs and $265-$315 million asset-related charges. Through September 30, 2017, $532 million of separation costs and $239 million of net asset-related charges incurred ($771 million total per MD&A). Charges for the three and nine months ended September 30, 2017 were not significant; remaining restructuring liability not significant. No employee counts disclosed in this filing.
2017-09-30restructuringin_progress2014United States (Washington State, Colorado, Thousand Oaks headquarters and other locations)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program initiated in 2014 to improve cost structure; estimated total pre-tax charges of $800M-$900M, including $535M-$585M of separation and headcount-related costs and $265M-$315M of asset-related charges. Through 2017-09-30, $532M of separation/headcount costs and $239M of net asset-related charges incurred. Charges in the three and nine months ended 2017-09-30 were not significant; restructuring liability not significant at period end. No employee counts disclosed.
2017-09-30restructuringin_progress2014GlobalVariousUSD 800 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Initiated in 2014. Estimated total pre-tax charges $800M-$900M. Includes separation/headcount costs ($535M-$585M) and asset-related charges ($265M-$315M). Through Sept 30, 2017, incurred $532M separation costs and $239M asset charges. Charges in Q3 2017 were not significant.
2017-09-30otherin_progress2017-092017-10-31Puerto RicoManufacturingUSD 67 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Hurricane Maria impact. Incurred $67M pre-tax expenses in Q3 2017. Expect additional $75M-$100M in Q4 2017. Staff accounted for, nearly all back at work. Manufacturing operations resuming.
2017-06-30restructuringin_progress2014-01-01USD 800 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2014 restructuring plan; expected pre-tax charges of $800-$900 million, including $535-$585 million separation/headcount costs and $265-$315 million asset-related charges. Cumulative costs of $760 million incurred through June 30, 2017 ($517 million separation and $243 million asset-related). Charges in the three and six months ended June 30, 2017 were not significant; total restructuring liability as of June 30, 2017 was not significant. No employee counts disclosed.
2017-06-30restructuringin_progress2014-01-01GlobalVariousUSD 760 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Initiated in 2014. Total pre-tax charges estimated at $800M-$900M. Through June 30, 2017, $517M incurred for separation/headcount costs and $243M for asset-related charges. Total incurred to date $760M. Specific employee counts for the period not disclosed.
2017-03-31restructuringin_progress2014-01-01United StatesUSD 800 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2014 restructuring plan; estimated total pre-tax charges of $800-$900 million, including $535-$585 million separation/headcount-related costs and $265-$315 million asset-related charges. Through March 31, 2017, $511 million of separation costs and $237 million of net asset-related charges incurred; quarterly charges and remaining liability not significant. Facilities closed in Washington State and Colorado; headquarters footprint reduced in Thousand Oaks, California. No employee counts disclosed.
2017-03-31restructuringin_progress2014United States (Washington State, Colorado, Thousand Oaks headquarters and other locations)Company-wideUSD 800 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program initiated 2014 with estimated total pre-tax charges of $800M-$900M, including $535M-$585M separation/headcount costs and $265M-$315M asset-related charges. Through 2017-03-31, $511M separation costs and $237M net asset charges incurred ($748M total per MD&A). No employee headcount affected is disclosed; Q1 2017 charges and remaining restructuring liability were not significant.
2017-03-31restructuringin_progress2014GlobalVariousUSD 800 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Initiated in 2014. Total pre-tax charges estimated at $800M-$900M. Includes separation costs ($535M-$585M) and asset-related charges ($265M-$315M). Through March 31, 2017, incurred $511M separation costs and $237M asset charges. Charges in Q1 2017 were not significant.
2016-12-31restructuringin_progress20142017United States (Washington, Colorado, California)Company-wide; filer operates a single human therapeutics segmentUSD 709 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year transformation and process improvement plan initiated in 2014. Filer presents cumulative-to-date figures: pre-tax charges of $709 million incurred through 2016-12-31, of an expected total of $800-900 million, with most remaining costs expected in 2017. Charges in fiscal 2016 alone were $37 million (per MD&A). Cumulative components include $477 million of separation and other headcount-related costs (expected total of $535-585 million for staff reductions) and $232 million of net asset-related charges; expected asset-related charges are $265-315 million. Facilities exited in Bothell/Seattle, Washington and Boulder/Longmont, Colorado, plus headquarters consolidation in Thousand Oaks, California. Number of employees affected is not disclosed. Restructuring liabilities of $20 million remained at 2016 year-end.
2016-12-31restructuringin_progress2017-12-31United StatesCompany-wideUSD 37 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Transformation and process improvement program announced in 2014; $37M charge incurred in FY2016, $709M cumulative through 2016-12-31 against an estimated $800M-$900M total. Includes facility closures in Washington and Colorado and building reductions in Thousand Oaks. No employees-affected count disclosed; most remaining costs expected in 2017.
2016-12-31restructuringin_progress20142017-12-31WorldwideVariousUSD 800 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Program initiated in 2014. Estimated total pre-tax charges $800M-$900M. $709M incurred through Dec 31, 2016. Most remaining costs expected in 2017. Specific employee count not disclosed in footnote.
2016-12-31restructuringin_progressUSD 19,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressEmployee Severance [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressOther Restructuring [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-09-30restructuringin_progress2014-01-012017-12-31United States (Washington, Colorado, California headquarters) and other worldwide locationsCompany-wide transformation and process improvementUSD 900 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program announced in 2014; estimated total pre-tax charges of $800-$900 million, comprising $535-$585 million separation and headcount-related costs and $265-$315 million asset-related charges from facility consolidation. Through September 30, 2016, $473 million of separation/headcount costs and $225 million of asset-related charges incurred; most remaining costs expected through 2017. Charges in Q3 2016 and YTD 2016 were not significant; restructuring liability not significant at quarter-end. No employee counts disclosed.
2016-09-30restructuringin_progress2014-01-012017-12-31United States (Washington state, Colorado, Thousand Oaks CA headquarters and other locations)Company-wideUSD 850 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Estimated pre-tax charges of $800M-$900M, including $535M-$585M separation/headcount and $265M-$315M asset-related; $473M separation and $225M asset charges incurred through 2016-09-30 ($698M total per MD&A). No employee count disclosed. Announcement date approximate (program announced in 2014; exact date not stated in filing).
2016-09-30restructuringin_progress20142017-12-31GlobalAll functionsUSD 698 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Ongoing transformation and process improvement efforts announced in 2014. Through Sept 30, 2016, incurred $473M separation/headcount costs and $225M asset-related charges. Total estimated pre-tax charges $800M-$900M. Most remaining costs expected through 2017. Specific employee count not disclosed.
2016-06-30restructuringin_progress2014-01-012017-12-31United States (Washington, Colorado, California headquarters) and worldwide facilitiesCompany-wide transformation and process improvementUSD 900 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Program announced in 2014; total estimated pre-tax charges of $800-$900 million, comprising $535-$585 million separation/headcount costs and $265-$315 million asset-related charges. Through June 30, 2016, $471 million separation costs and $213 million asset charges incurred ($684 million total). Remaining costs expected mostly in remainder of 2016 and 2017. Restructuring liability decreased to $35 million as of June 30, 2016. Charges in Q2 and H1 2016 were not significant. No employee count disclosed.
2016-06-30restructuringin_progress20142017-12-31United States (Washington state, Colorado, Thousand Oaks, California headquarters and other locations)Company-wide transformation and process improvement programrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Estimated pre-tax charges of $800M-$900M ($535M-$585M separation/headcount; $265M-$315M asset-related); $684M incurred through 2016-06-30 ($471M separation, $213M asset). No employee count disclosed; restructuring liability was $35M at quarter-end; most remaining costs expected in remainder of 2016 and 2017.
2016-06-30restructuringin_progress20142017-12-31GlobalAll functionsUSD 684 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program announced in 2014. Through June 30, 2016, $471M incurred for separation/headcount costs and $213M for asset-related charges. Total estimated pre-tax charges $800M-$900M. Remaining costs expected in remainder of 2016 and 2017. Specific employee count not disclosed in this filing.
2016-03-31restructuringin_progress2014-01-012017-12-31United StatesCompany-wideUSD 900 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Transformation program announced 2014; estimated total pre-tax charges of $800-$900 million, including $535-$585 million separation/headcount-related costs and $265-$315 million asset-related charges. Through March 31, 2016, $463 million of separation costs and $205 million of asset-related charges incurred; most remaining costs expected in 2016-2017. Facilities closing in Washington state and Colorado and buildings reduced at Thousand Oaks headquarters. Quarterly charges in Q1 2016 were not significant; restructuring liability decreased to $38 million.
2016-03-31restructuringin_progress2014-01-012017-12-31United States (Washington state, Colorado, Thousand Oaks CA headquarters and other locations)Company-wide transformation and process improvement programUSD 850 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Estimated $800M–$900M total pre-tax charges (midpoint shown); $668M incurred through 2016-03-31 ($463M separation/headcount, $205M asset-related). No employee count disclosed. Charges in Q1 2016 not significant; restructuring liability $38M at quarter-end. Program announced in 2014; announcement_date is approximate (year only).
2016-03-31restructuringin_progress20142017-12-31GlobalCorporate / HeadquartersUSD 800 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Ongoing transformation and process improvement efforts announced in 2014. Estimated total pre-tax charges of $800M-$900M. Through March 31, 2016, $463M incurred for separation/headcount costs and $205M for asset-related charges. Remaining costs expected in 2016 and 2017. Specific employee count for Q1 2016 not disclosed.
2015-12-31restructuringin_progress3,5002014United States (Washington, Colorado, Thousand Oaks California); broader geographic footprint reductionCompany-wide (single reportable segment: human therapeutics)USD 114 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Transformation/restructuring program initiated in H2 2014; planned staff reduction range is 3,500 to 4,000 (value shown is low end of disclosed range). Involves closing facilities in Washington (Bothell, Seattle) and Colorado (Boulder, Longmont) and consolidating buildings at the Thousand Oaks, California headquarters. FY2015 restructuring charge was $114 million; cumulative charges through December 31, 2015 were $672 million ($478M separation/headcount-related, $194M net asset-related) against a total estimated pre-tax program cost of $800–900 million. Remaining costs expected mostly in 2016 and 2017.
2015-12-31acquisition_additioncompleted2015-10-14NetherlandsHuman therapeutics — cardiovascular portfoliobusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Amgen acquired all outstanding stock of Dezima Pharma B.V., a Netherlands-based biotechnology company, on October 14, 2015 (total consideration $410 million); operations consolidated from the acquisition date. Acquired employee headcount was not disclosed.
2015-12-31restructuringin_progress20142017-12-31United StatesCompany-wideUSD 114 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program announced in the second half of 2014; MD&A states a staff reduction target of 3,500 to 4,000 (count not stated as a single figure in the footnote). Charge shown is FY2015 restructuring cost; program estimated at $800-900 million pre-tax total, with $672 million incurred cumulatively through 2015-12-31. Program includes closing facilities in Washington state and Colorado and reducing buildings occupied at the Thousand Oaks, California headquarters and other locations; most remaining costs expected in 2016 and 2017.
2015-12-31plant_closurein_progress20142017-12-31United States (Washington, Colorado, California)Manufacturing and R&D facilitiesrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Facility closures and site consolidation are a component of the same restructuring program; no separately disclosed headcount or charge, to avoid double-counting with the restructuring record above. FY2015 included $100 million of accelerated depreciation and net asset-related gains from site-closure asset sales within the $114 million total.
2015-12-31acquisition_additioncompleted2015-10-142015-10-14NetherlandsCardiovascular research and developmentbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of all outstanding stock of Dezima Pharma B.V. completed 2015-10-14; acquired headcount not disclosed. Total consideration $410 million ($300 million cash plus $110 million contingent consideration fair value).
2015-12-31restructuringin_progress3,7502014-07-012017-12-31WorldwideAll functionsUSD 114 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Plan announced in H2 2014 to reduce staff by 3,500 to 4,000. $114M incurred in 2015. Total estimated pre-tax charges $800M-$900M. Most remaining costs expected in 2016-2017.
2015-12-31restructuringin_progressUSD 132,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressEmployee Severance [Member]USD 52,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressOther Restructuring [Member]USD 80,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-09-30restructuringin_progress2014-07-012016-12-31United StatesManufacturing and R&D facilitiesUSD 935 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan initiated in H2 2014; estimated total pre-tax charges of $935M-$1,035M, including $535M-$585M separation/headcount costs and $400M-$450M asset-related charges. $724M incurred through 2015-09-30; Q3 2015 charge $11M, YTD $166M. Involves closing facilities in Washington State and Colorado and consolidating buildings at Thousand Oaks, CA headquarters; remaining costs expected in remainder of 2015 and 2016. No employee counts disclosed.
2015-09-30plant_closurein_progress2014-07-012016-12-31United StatesManufacturing and R&DUSD 400 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Asset impairments and accelerated depreciation from exiting Boulder and Longmont, Colorado and Bothell and Seattle, Washington, plus consolidation of Thousand Oaks, California facilities; estimated asset-related charges of $400M-$450M. $242M incurred through 2015-09-30. Q3 2015 included a $32M gain on sale of assets related to site closures. No employee counts disclosed.
2015-09-30acquisition_additionannounced2015-10-14NetherlandsR&D (dyslipidemia)USD 300 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Dezima Pharma B.V. on 2015-10-14 for $300M cash plus up to $1.25B in milestone payments; to be accounted for as a business combination. No headcount figures disclosed.
2015-09-30restructuringin_progress2014United States (Washington State, Colorado, Thousand Oaks CA)Manufacturing and research and development facilities; corporate headquartersUSD 935 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan initiated in second half of 2014; estimated total pre-tax charges range $935M–$1,035M (separation/headcount $535M–$585M; asset-related $400M–$450M). $482M separation and $242M asset-related charges incurred through 2015-09-30; $11M incurred in Q3 2015 and $166M in YTD 2015. No employee counts disclosed. Remaining costs expected during remainder of 2015 and in 2016. Closures include Boulder and Longmont, CO and Bothell and Seattle, WA, plus building consolidation at Thousand Oaks, CA headquarters.
2015-09-30acquisition_additionannounced2015-10-142015-10-14NetherlandsResearch and development (dyslipidemia; lead molecule TA-8995)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Dezima Pharma B.V. closed 2015-10-14 for $300M cash plus up to $1.25B in milestone payments and low single-digit royalties; to be accounted for as a business combination. No headcount disclosed; purchase price allocation not yet available.
2015-09-30restructuringin_progress2014-07-012016-12-31GlobalGlobalUSD 11 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Initiated in H2 2014. Q3 2015 charges of $11M. Total estimated pre-tax charges $935M-$1,035M. Remaining costs expected in remainder of 2015 and 2016.
2015-09-30restructuringin_progressUSD 115,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressEmployee Severance [Member]USD 59,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressOther Restructuring [Member]USD 56,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progress2014-07-012015-12-31United StatesCompany-wideUSD 935 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan initiated in second half of 2014; estimated pre-tax charges of $935M-$1,035M, comprising $535M-$585M separation/headcount costs and $400M-$450M asset-related charges. $713M incurred through June 30, 2015; most remaining costs expected in remainder of 2015. No employee counts disclosed.
2015-06-30plant_closurein_progress2014-07-012015-12-31Washington State and Colorado; Thousand Oaks, CaliforniaManufacturing and R&D facilitiesUSD 400 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Closing facilities in Washington State and Colorado and reducing buildings occupied at Thousand Oaks headquarters; asset-related charges of $400M-$450M (impairments, accelerated depreciation). Expansion of presence in South San Francisco, CA and Cambridge, MA. No headcount figures disclosed.
2015-06-30restructuringin_progress2015-12-31United States (Washington State, Colorado, Thousand Oaks CA and other locations)Company-wide (manufacturing, R&D and headquarters facilities)USD 935 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program initiated in second half of 2014; estimated pre-tax charges of $935M-$1,035M, of which $713M incurred through 2015-06-30. Includes separation/headcount costs of $535M-$585M and asset-related charges of $400M-$450M. No employee headcount affected is disclosed. $63M charged in Q2 2015 and $155M in YTD 2015; restructuring liabilities of $159M at 2015-06-30. Most remaining costs expected during remainder of 2015.
2015-06-30othercompleted2015-05-012015-06-30United StatesCommercial — Nexavar collaboration (Sales & Marketing, medical affairs)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Amgen-Bayer amendment terminated the U.S. co-promotion agreement effective 2015-06-30, transferring U.S. commercial responsibilities to Bayer; Amgen no longer contributes sales force personnel or medical liaisons for Nexavar in the U.S. No employee count or charge disclosed; profit share replaced by a royalty in the high 30s percent range.
2015-06-30restructuringin_progress2014-07-012015-12-31United StatesGlobalUSD 155 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan initiated in H2 2014 to invest in innovation and improve cost structure. Includes closing facilities in Washington State, Colorado, and Thousand Oaks, CA. Total estimated pre-tax charges $935M-$1,035M. $155M incurred in Q2 2015 (YTD $713M). Employee count not disclosed.
2015-06-30restructuringin_progressUSD 95,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressEmployee Severance [Member]USD 56,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressOther Restructuring [Member]USD 39,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progress2014-07-012015-12-31United StatesUSD 92 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan initiated in second half of 2014; staff reduction of 3,500 to 4,000 positions targeted by end of 2015. Cumulative pre-tax charges of $650 million incurred through March 31, 2015 against an estimated total of $935 million to $1,035 million; substantially all remaining actions expected during the remainder of 2015.
2015-03-31plant_closurein_progress2014-07-012015-12-31Washington and Colorado, United StatesManufacturing and R&D facilitiesUSD 400 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Closures of Boulder and Longmont, Colorado and Bothell and Seattle, Washington facilities, plus reduction of buildings at Thousand Oaks, California headquarters. Asset-related charges estimated at $400 million to $450 million (primarily impairments and accelerated depreciation); Q1 2015 accelerated depreciation of $28 million recognized across cost of sales, R&D and SG&A.
2015-03-31reduction_in_forcein_progress2014-07-012015-12-31United StatesUSD 535 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Separation costs estimated at $535 million to $585 million for the planned staff reduction of 3,500 to 4,000 employees. Q1 2015 separation expense of $48 million recognized in Other operating expenses; restructuring liabilities of $170 million for separation costs as of March 31, 2015.
2015-03-31restructuringin_progress2014-07-012015-12-31United StatesCompany-wide (staff reductions, Washington and Colorado facility closures, Thousand Oaks headquarters consolidation)USD 985 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan announced in H2 2014; targets staff reduction of 3,500 to 4,000 by end of 2015. Estimated total pre-tax charges of $935M to $1,035M (midpoint shown); $650M incurred through 2015-03-31, including $92M in Q1 2015. Announcement date is approximate (second half of 2014; exact date not disclosed).
2015-03-31restructuringin_progress2014-07-012015-12-31United StatesGlobalUSD 92 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan initiated in H2 2014 to reduce staff by 3,500 to 4,000 by end of 2015. $92M incurred in Q1 2015. Total estimated pre-tax charges $935M-$1,035M.
2015-03-31restructuringin_progressUSD 57,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressEmployee Severance [Member]USD 48,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressOther Restructuring [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progress4,000Maximum [Member]restructuring_footnote
f5-10q / no-ai-xblr		Expected positions to be eliminated
2015-03-31restructuringin_progress3,500Minimum [Member]restructuring_footnote
f5-10q / no-ai-xblr		Expected positions to be eliminated
2014-12-31restructuringin_progress20142015-12-31Company-wideCompany-wide (single operating segment: human therapeutics)USD 377 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Program announced and initiated during H2 2014 to reduce staff by 3,500 to 4,000 positions by end of 2015; headcount disclosed only as a range, hence count left null. Separation costs of $377M incurred in 2014 against estimated program separation costs of $535M–$585M; total program pre-tax charges estimated at $935M–$1,035M, with substantially all remaining actions and costs expected in 2015. Restructuring liabilities of $244M (of which $221M separation) at year-end 2014.
2014-12-31plant_closurein_progress20142015-12-31United States (Bothell and Seattle, Washington; Boulder and Longmont, Colorado; Thousand Oaks, California)Manufacturing and R&D facilitiesrestructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Facility exits and headquarters consolidation within the same H2 2014 program; company-wide facilities footprint reduction of approximately 23%. Expected asset-related charges (impairments, accelerated depreciation) of $400M–$450M, disclosed only as a range; 2014 recognized charges include $87M asset impairments and $55M accelerated depreciation. Headcount impact is included in the program-wide 3,500–4,000 position reduction (see related restructuring record).
2014-12-31restructuringin_progress3,50020142015-12-31USD 558 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program announced in second half of 2014 targets a staff reduction of 3,500 to 4,000 positions by end of 2015 (lower bound shown). FY2014 charge of $558M includes $377M separation costs, $87M asset impairments, $55M accelerated depreciation and $39M other; total program estimated at $935M to $1,035M pre-tax, with substantially all remaining actions and costs expected in 2015. Also includes reducing buildings at Thousand Oaks, CA headquarters (~23% facilities footprint reduction).
2014-12-31plant_closureannounced20142015-12-31Washington, United StatesManufacturing and R&D (Bothell and Seattle sites)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Facility closures in Washington state are part of the same 2014 restructuring program; asset impairment and accelerated depreciation charges recognized for exit of Bothell and Seattle sites. No separate employee count disclosed.
2014-12-31plant_closureannounced20142015-12-31Colorado, United StatesManufacturing and R&D (Boulder and Longmont sites)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Facility closures in Colorado are part of the same 2014 restructuring program; asset impairment and accelerated depreciation charges recognized for exit of Boulder and Longmont sites. No separate employee count disclosed.
2014-12-31restructuringin_progress3,7502014-06-302015-12-31WorldwideAll functionsUSD 985 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Announced in second half of 2014. Plan to reduce staff by 3,500 to 4,000 by end of 2015. Estimated pre-tax charges $935M-$1,035M. Incurred $558M in 2014. Includes closure of facilities in Washington state and Colorado and reduction of headquarters footprint.
2014-12-31restructuringin_progressUSD 385,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressEmployee Severance [Member]USD 353,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressOther Restructuring [Member]USD 32,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress4,000Maximum [Member]restructuring_footnote
f5-10k / no-ai-xblr		Expected positions to be eliminated
2014-12-31restructuringin_progress3,500Minimum [Member]restructuring_footnote
f5-10k / no-ai-xblr		Expected positions to be eliminated
2014-09-30restructuringin_progress2014-07-292015-12-31WorldwideCompany-wideUSD 935 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan expanded from initial 2,400-2,900 staff reduction to 3,500-4,000 by end of 2015; total estimated charges $935M-$1,035M (separation costs $535M-$585M; asset-related charges $400M-$450M); ~55% cash. $376M incurred in Q3 2014; remaining actions expected in Q4 2014 and 2015.
2014-09-30plant_closurein_progress2014-07-292015-12-31Washington and Colorado, United StatesManufacturing and R&D facilitiesUSD 400 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Exit of Boulder and Longmont, Colorado and Bothell and Seattle, Washington, plus consolidation of Thousand Oaks, California facilities; asset-related charges of $400M-$450M (asset impairments, accelerated depreciation). Q3 charges: $17M impairments and $29M accelerated depreciation.
2014-09-30reduction_in_forcein_progress2014-07-292015-12-31WorldwideCompany-wideUSD 535 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Staff reduction of 3,500-4,000 by end of 2015; separation costs estimated at $535M-$585M. Q3 2014 separation expense of $323M recorded (liability of $309M at September 30, 2014); severance payments not yet made as of quarter-end.
2014-09-30restructuringin_progress3,5002014-07-292015-12-31United States (Washington, Colorado, Thousand Oaks, California)Company-wideUSD 935 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Planned staff reduction range of 3,500 to 4,000 by end of 2015 (lower bound shown); original July 29, 2014 plan of 2,400 to 2,900 was expanded on October 28, 2014. Total estimated charges range $935M to $1,035M (separation $535M-$585M; asset-related $400M-$450M); approximately 55% of charges will be cash. Includes closure of Washington state and Colorado facilities and consolidation of Thousand Oaks buildings (~23% facilities footprint reduction). $376M of charges incurred in Q3 2014; substantially all remaining actions expected in Q4 2014 and 2015.
2014-09-30restructuringin_progress2014-07-292015-12-31GlobalAll functionsUSD 935 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan to reduce staff by 3,500 to 4,000 by end of 2015. Total estimated charges $935M-$1,035M. $376M incurred in Q3 2014. Includes separation costs and asset impairments.
2014-09-30restructuringin_progressUSD 312,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressOther Restructuring [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressEmployee Severance [Member]USD 309,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progress3,500Minimum [Member]restructuring_footnote
f5-10q / no-ai-xblr		Expected positions to be eliminated
2014-09-30restructuringin_progress4,000Maximum [Member]restructuring_footnote
f5-10q / no-ai-xblr		Expected positions to be eliminated
2014-06-30restructuringannounced2014-07-292015-12-31Global (Washington state, Colorado, and Thousand Oaks, California headquarters)Company-widesubsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Staff reduction of 2,400 to 2,900 positions by end of 2015; facilities in Washington and Colorado to close and headquarters buildings reduced. Pre-tax charges estimated at $775 million to $950 million, primarily in 2014 and 2015, comprising $400-$500 million accelerated depreciation/asset impairment and $375-$450 million staff reduction charges; approximately 40% of total charges expected to be cash, mainly separation costs. Range disclosed rather than a single count, so no single employees_affected_count is recorded.
2014-06-30restructuringannounced2014-07-292015-12-31United States (worldwide program)Company-widesubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Staff reduction disclosed only as a range of 2,400 to 2,900 positions by end of 2015 (count field left null because a single value cannot represent the range). Program also closes facilities in Washington state and Colorado and reduces headquarters buildings in Thousand Oaks, CA (~23% facilities footprint reduction). Expected pre-tax charges of $775M to $950M, primarily in 2014 and 2015, comprising $400M-$500M accelerated depreciation/asset impairment and $375M-$450M for staff reductions; approximately 40% of total charges will be cash. Also disclosed in MD&A Restructuring discussion and as a new risk factor in Part II, Item 1A — extracted once here.
2014-06-30restructuringin_progressCompany-wideUSD 38 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cost savings initiatives incurred severance-heavy charges of $23 million in the three months ended 2014-06-30 and $38 million for the six months ended 2014-06-30 (charge value shown is the year-to-date figure). Number of employees affected, announcement date, and completion timing not disclosed.
2014-06-30restructuringannounced2014-07-012015-12-31United StatesCorporate / Headquarterssubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Announced July 2014. Plan to reduce staff by 2,400 to 2,900 by end of 2015. Close facilities in Washington and Colorado. Reduce buildings at Thousand Oaks HQ. Pre-tax charges estimated at $775 million to $950 million, primarily incurred in 2014 and 2015.
2013-12-31restructuringin_progressUSD 71 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year cost-efficiency program; charges of approximately $71 million in 2013, $175 million in 2012 and $109 million in 2011 recorded in Other operating expenses, primarily severance-related. Only the FY2013 charge is captured. Number of employees affected not disclosed.
2013-12-31acquisition_additioncompleted2013-10-01Oncologybusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired all outstanding stock of Onyx Pharmaceuticals, Inc. on October 1, 2013 (date shown is acquisition completion date; deal announcement date not disclosed in filing). Total cash paid of $9,712 million included $197 million of compensation expense for accelerated vesting of Onyx equity awards. Headcount added through the acquisition was not disclosed.
2013-12-31acquisition_additioncompleted2013-10-012013-10-01United StatesHuman therapeutics (oncology)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Onyx Pharmaceuticals closed October 1, 2013; headcount added not disclosed. Related transaction and integration costs of $36 million plus $197 million accelerated-vesting compensation were recorded in SG&A.
2013-12-31restructuringin_progress2013-12-31Not disclosedCompany-wide cost savings initiativesUSD 71 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approximately $71 million of charges recorded in 2013, primarily severance-related, within Other operating expenses; number of employees affected and completion timeline not disclosed.
2013-12-31othercompleted2013-10-012014-01-01Eastern Europe, Latin America, Asia, Middle East, AfricaCommercial (filgrastim and pegfilgrastim licenses)USD 479 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire Roche's filgrastim/pegfilgrastim licenses in approximately 100 markets for $479 million cash, effective January 1, 2014; treated as a business combination. Headcount impact not disclosed.
2013-12-31restructuringcompleted2013-01-012013-12-31GlobalVariousUSD 71 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Charges related to cost savings initiatives, primarily severance expenses, totaling $71 million in 2013. Employee count not disclosed.
2013-09-30restructuringin_progressUSD 35 (millions)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Cost savings initiative charges of $35 million for the quarter, primarily severance; no employee counts disclosed. YTD charge was $46 million.
2013-09-30acquisition_additionannounced2013-10-012013-10-01OncologyUSD 9,700 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Onyx Pharmaceuticals acquisition completed October 1, 2013 for approximately $9.7 billion net cash; no headcount figures disclosed.
2013-09-30restructuringin_progressUSD 46 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Nine-month 2013 charge of $46M for cost savings initiatives, described as primarily severance; no employee count or completion date disclosed. Q3-only charge was $35M.
2013-09-30acquisition_additioncompleted2013-10-012013-10-01United StatesHuman therapeuticssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Onyx Pharmaceuticals acquired 2013-10-01 for ~$9.7B net cash; no headcount added disclosed and purchase price allocation not yet complete.
2013-09-30restructuringin_progressUSD 35 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Charges for certain cost savings initiatives, primarily severance, included in Other operating expenses for the three months ended September 30, 2013.
2013-09-30restructuringin_progressUSD 46 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Charges for certain cost savings initiatives, primarily severance, included in Other operating expenses for the nine months ended September 30, 2013.
2012-12-31restructuringcompletedUSD 175 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Cost savings charges recognized in Other operating expenses during FY2012; primarily severance-related plus leased-facility exit costs. No employee count disclosed. Commitments footnote also shows $331 million of future rental commitments for abandoned leases at year-end.
2012-12-31plant_closurecompletedBoulder, Colorado, United StatesManufacturingUSD 118 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Facilities determined no longer needed and abandoned in Q4 2012 to optimize the manufacturing network; charge is a write-off of facility carrying value recorded in Cost of sales. No headcount affected disclosed.
2012-12-31restructuringin_progressGlobalOperations / corporate functionsUSD 175 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2012 charges of approximately $175 million, primarily severance-related and charges for exiting leased facilities; employee counts not disclosed. Prior-year (2011) comparable charges of $109 million excluded.
2012-12-31plant_closurecompleted2012-12-31United States (Boulder, Colorado)ManufacturingUSD 118 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Boulder, Colorado manufacturing facilities determined no longer needed and abandoned in Q4 2012; $118 million carrying value written off in cost of sales. Workforce impact not quantified.
2012-12-31acquisition_additioncompleted2012-03-072012-03-07United StatesOncology R&DUSD 1,146 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition consideration of $1,146 million in cash; acquired headcount not disclosed.
2012-12-31acquisition_additioncompleted2012-06-122012-06-12TurkeyCommercial / manufacturing (hospital and injectable medicines)USD 677 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition consideration of $677 million in cash; acquired headcount not disclosed.
2012-12-31acquisition_additioncompleted2012-07-052012-07-05United StatesNephrology R&DUSD 332 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition consideration of $332 million in cash; acquired headcount not disclosed.
2012-12-31acquisition_additioncompleted2012-12-102012-12-10IcelandHuman genetics researchUSD 401 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition consideration of $401 million in cash; acquired headcount not disclosed.
2012-12-31restructuringcompleted2012-12-312012-12-31GlobalVariousUSD 175 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Charges related to cost savings initiatives including severance and expenses associated with abandoning leased facilities.
2012-12-31plant_closurecompleted2012-12-312012-12-31Boulder, ColoradoManufacturingUSD 118 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Abandonment of manufacturing facilities in Boulder, Colorado; write-off of carrying value.
2012-09-30restructuringin_progressUSD 36 (millions)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Cost savings initiative charges of $36 million for the quarter and $106 million year-to-date included in Other operating expenses; no employee counts disclosed.
2012-09-30acquisition_additioncompleted2012-03-07OncologyUSD 1,146 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Micromet, Inc. for $1,146 million cash; headcount added not disclosed.
2012-09-30acquisition_additioncompleted2012-06-12TurkeyUSD 677 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired 99.4% of Mustafa Nevzat Pharmaceuticals for $677 million cash; headcount added not disclosed.
2012-09-30acquisition_additioncompleted2012-07-05NephrologyUSD 332 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of KAI Pharmaceuticals for $332 million cash; headcount added not disclosed.
2012-09-30acquisition_additioncompleted2012-03-07United StatesOncology R&DUSD 1,146 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cash consideration of $1,146M; no employee count disclosed for the acquired workforce.
2012-09-30acquisition_additionin_progress2012-06-12TurkeyPharmaceuticals manufacturing and salesUSD 677 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of 99.4% of outstanding stock for $677M cash; accounting still preliminary; no headcount disclosed.
2012-09-30acquisition_additioncompleted2012-07-05United StatesNephrology R&DUSD 332 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cash consideration of $332M; no employee count disclosed for the acquired workforce.
2012-09-30restructuringin_progressUSD 36 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cost savings initiative charges of $36M in Q3 2012 and $106M YTD 2012, recorded in Other operating expenses; no employee counts or completion dates disclosed.
2012-06-30acquisition_additioncompleted2012-03-072012-03-07OncologyUSD 1,146 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired Micromet, Inc. for $1,146 million cash; became wholly owned subsidiary Amgen Rockville, Inc. No headcount figures disclosed.
2012-06-30acquisition_additioncompleted2012-06-122012-06-12TurkeyUSD 677 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired 99.4% of Mustafa Nevzat Pharmaceuticals for $677 million cash; no headcount figures disclosed.
2012-06-30acquisition_additioncompleted2012-07-052012-07-05NephrologyUSD 330 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Subsequent event: acquired KAI Pharmaceuticals for approximately $330 million cash, subject to closing adjustments; no headcount figures disclosed.
2012-06-30restructuringin_progressUSD 69 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cost savings initiative charges of $69 million (Q2) and $70 million (six months) in Other operating expenses; no employee counts disclosed.
2012-06-30restructuringin_progressUSD 70 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charges for cost savings initiatives of $69 million (three months) and $70 million (six months) recorded in Other operating expenses; no employee counts, geographies, or completion timing disclosed
2012-06-30acquisition_additioncompleted2012-03-072012-03-07United StatesOncologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired March 7, 2012 for $1,146 million cash; headcount added not disclosed
2012-06-30acquisition_additioncompleted2012-06-122012-06-12Turkeybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired 99.4% of outstanding stock June 12, 2012 for $677 million cash; headcount added not disclosed
2012-06-30acquisition_additioncompleted2012-07-052012-07-05United StatesNephrologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent-event acquisition completed July 5, 2012 (after quarter end) for approximately $330 million cash; headcount added not disclosed
2012-06-30acquisition_additioncompleted2012-03-07GlobalOncologyUSD 1,146 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Micromet, Inc. on March 7, 2012. Headcount not disclosed.
2012-06-30acquisition_additioncompleted2012-06-12TurkeyPharmaceuticalsUSD 677 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Mustafa Nevzat Pharmaceuticals on June 12, 2012. Headcount not disclosed.
2012-06-30acquisition_additionannounced2012-07-05GlobalNephrologyUSD 330 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquired KAI Pharmaceuticals on July 5, 2012 (subsequent event). Headcount not disclosed.
2012-03-31acquisition_additioncompleted2012-03-072012-03-07Oncologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Wholly owned subsidiary acquired for $1,146 million cash; no headcount added disclosed.
2012-03-31acquisition_additionannounced2012-04-10Nephrologysubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire KAI for $315 million cash at closing; subject to closing conditions.
2012-03-31acquisition_additionannounced2012-04-25Turkeysubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire at least 95.6% of MN, valuing it at $700 million, all cash.
2011-12-31restructuringcompletedUSD 109 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Approximately $109 million of charges, primarily severance-related, recorded during fiscal 2011 under continuing cost-efficiency efforts; included in Other operating expenses. Number of employees affected not disclosed.
2011-12-31othercompleted2011-01-182011-03Fremont, California, United StatesManufacturingrestructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Boehringer Ingelheim agreed to acquire Amgen's rights and substantially all assets at the Fremont manufacturing facility; transaction closed in March 2011. Workforce impact not quantified. Fiscal 2011 related charges included roughly $42 million of incremental depreciation and $23 million of lease-related charges.
2011-12-31acquisition_additioncompleted2011-03-042011-03-04Oncology R&Dbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired BioVex, a private biotechnology company developing talimogene laherparepvec, a phase 3 oncolytic vaccine for melanoma; total consideration $597 million. Headcount added not disclosed.
2011-12-31acquisition_additioncompleted2011-04-072011-04-07BrazilPharmaceuticals (hospital sector, oncology)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired Bergamo, a private Brazilian pharmaceutical company supplying medicines to the hospital sector; headcount added not disclosed.
2011-12-31acquisition_additioncompleted2011-05-162011-05-16IrelandManufacturingbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired a manufacturing facility in Dun Laoghaire from Pfizer; under the agreement most staff at the facility became Amgen employees. Headcount not quantified.
2011-12-31acquisition_additioncompleted2011-06-152011-06-15BrazilCommercial operationsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Reacquired Brazilian distribution rights from the local distributor and Hypermarcas and acquired the related business operations in Brazil; headcount impact not disclosed.
2011-12-31acquisition_additionannounced2012-01-262012-03-31Oncology (blinatumomab, BiTE antibody technology)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Agreement to acquire Micromet at $11 per share in cash, valuing the company near $1.16 billion; closing expected during the quarter ending March 31, 2012. Headcount impact not disclosed.
2011-12-31restructuringin_progressWorldwideOperations (primarily severance-related)USD 109 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Charges recorded during FY2011 as part of continuing cost-efficiency efforts; headcount affected and completion timeline not disclosed. Separate from the 2007 restructuring plan, which was completed in 2009.
2011-12-31plant_closurecompleted2011-01-182011-03-31United States (Fremont, California)Manufacturingrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement for Boehringer Ingelheim to acquire rights to and substantially all assets at the Fremont facility; transaction closed March 2011. Filer recorded $42 million of incremental depreciation and approximately $23 million of lease-related charges in FY2011; a $118 million asset impairment on an incomplete manufacturing line was recorded in FY2010. Headcount affected not disclosed.
2011-12-31acquisition_additioncompleted2011-03-042011-03-04United StatesResearch and development (oncolytic vaccine platform)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired all outstanding stock of BioVex for $597 million total consideration; headcount added not disclosed.
2011-12-31acquisition_additioncompleted2011-04-072011-04-07BrazilCommercial operations (oncology hospital sector)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired all outstanding stock of Bergamo; headcount added not disclosed.
2011-12-31acquisition_additioncompleted2011-05-162011-05-16Ireland (Dun Laoghaire)Manufacturingbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchased manufacturing facility from Pfizer; filer states most staff at the facility became Amgen employees. Headcount added not disclosed.
2011-12-31acquisition_additioncompleted2011-06-152011-06-15BrazilCommercial operations (distribution)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Reacquired rights to distribute certain products in Brazil and acquired related business operations; headcount added not disclosed.
2011-12-31acquisition_additionannounced2012-01-262012-03-31United StatesResearch and development (oncology / BiTE antibody platform)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Tender offer at $11.00 per share valuing Micromet at approximately $1.16 billion; expected to close in Q1 2012. Announced after fiscal year-end but before the filing date; headcount added not disclosed.
2011-12-31restructuringcompleted2011-01-182011-12-31United StatesManufacturingUSD 109 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charges primarily severance-related recorded in 2011 as part of continuing efforts to improve cost efficiencies.
2011-12-31acquisition_additioncompleted2011-03-042011-03-04GlobalResearch and Developmentbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of BioVex Group, Inc. Headcount not explicitly disclosed.
2011-12-31acquisition_additioncompleted2011-04-072011-04-07BrazilCommercial Operationsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Laboratório Químico Farmacêutico Bérgamo Ltda. Headcount not explicitly disclosed.
2011-12-31acquisition_additioncompleted2011-05-162011-05-16IrelandManufacturingbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of manufacturing facility in Dun Laoghaire from Pfizer. Most staff became Amgen employees.
2011-12-31acquisition_additioncompleted2011-06-152011-06-15BrazilCommercial Operationsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Reacquisition of distribution rights and business operations in Brazil from Hypermarcas. Headcount not explicitly disclosed.
2011-09-30restructuringin_progressUSD 68 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance-related charges of approximately $68 million (three months) and $79 million (nine months) under cost-efficiency initiatives; employee counts not disclosed.
2011-09-30plant_closurecompleted2011-01-182012-12-31Fremont, CaliforniaManufacturingUSD 31 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Rights in Fremont manufacturing operations transferred to Boehringer Ingelheim in March 2011; BI to supply Vectibix through 2012. Incremental depreciation of ~$10M (Q3) and ~$31M (nine months) plus ~$23M lease-related charges; headcount transfer not disclosed.
2011-09-30acquisition_additioncompleted2011-03-04United StatesOncology (talimogene laherparepvec)USD 597 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of BioVex Group, Inc. for total consideration of $597 million; headcount added not disclosed.
2011-09-30acquisition_additioncompleted2011-04-07Brazilbusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Laboratorio Quimico Farmaceutico Bergamo Ltda; headcount added not disclosed.
2011-09-30acquisition_additioncompleted2011-05-16Dun Laoghaire, IrelandManufacturingbusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Manufacturing facility acquired from Pfizer; most facility staff became Amgen employees, but headcount not quantified.
2011-09-30acquisition_additioncompleted2011-06-15Brazilbusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of certain business operations from Hypermarcas; aggregate consideration for Bergamo, Dun Laoghaire and Hypermarcas approximately $453 million; headcount added not disclosed.
2011-09-30restructuringin_progressUSD 68 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cost-efficiency charges described as primarily severance-related, recorded in Other operating expenses for the three months ended September 30, 2011; the nine-month charge was $79 million. No employee count, geography, or completion date disclosed.
2011-09-30acquisition_additioncompleted2011-03-04United Statesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of all outstanding stock of BioVex completed March 4, 2011; BioVex became a wholly owned subsidiary. No employee count disclosed; $7 million expensed to settle unvested employee options.
2011-09-30acquisition_additioncompleted2011-04-07Brazilbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Laboratorio Quimico Farmaceutico Bergamo Ltda completed April 7, 2011; became a wholly owned subsidiary. No employee count disclosed.
2011-09-30acquisition_additioncompleted2011-05-16IrelandManufacturingbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired a manufacturing facility in Dun Laoghaire from Pfizer completed May 16, 2011; most facility staff transitioned to Amgen employment. No employee count disclosed.
2011-09-30acquisition_additioncompleted2011-06-15Brazilbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Reacquired rights to distribute certain products in the Brazilian market upon acquiring business operations from Hypermarcas, completed June 15, 2011. No employee count disclosed.
2011-09-30restructuringcompleted2011-01-18Fremont, CaliforniaManufacturingUSD 68 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily severance-related recorded in Other operating expenses for the three months ended Sept 30, 2011. Part of broader cost savings initiatives.
2011-09-30restructuringcompleted2011-01-01GlobalCorporateUSD 79 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily severance-related recorded in Other operating expenses for the nine months ended Sept 30, 2011. Part of broader cost savings initiatives.
2011-09-30acquisition_additioncompleted2011-03-04United StatesBiotechnologybusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of BioVex Group, Inc. Employees became Amgen employees upon acquisition.
2011-09-30acquisition_additioncompleted2011-04-07BrazilPharmaceuticalsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Laboratorio Quimico Farmaceutico Bergamo Ltda. Became wholly owned subsidiary.
2011-09-30acquisition_additioncompleted2011-05-16IrelandManufacturingbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of manufacturing facility in Dun Laoghaire from Pfizer. Most staff became Amgen employees.
2011-09-30acquisition_additioncompleted2011-06-15BrazilDistributionbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reacquired rights to distribute products in Brazil via acquisition of operations from Hypermarcas.
2011-06-30acquisition_additioncompleted2011-03-04United StatesOncology/oncolytic vaccine development (BioVex)USD 597 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		BioVex became a wholly owned subsidiary; headcount added not quantified. Total consideration $597M including $190M contingent consideration.
2011-06-30acquisition_additioncompleted2011-04-07BrazilBrazilian pharmaceutical operations (Bergamo)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Bergamo became a wholly owned subsidiary; employee headcount added not quantified.
2011-06-30acquisition_additioncompleted2011-05-16IrelandManufacturing (Dun Laoghaire facility acquired from Pfizer)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Most staff at the acquired Pfizer facility became Amgen employees; headcount not quantified.
2011-06-30acquisition_additioncompleted2011-06-15BrazilBrazilian pharmaceutical distribution (Hypermarcas business operations)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Reacquired rights to distribute certain products in Brazil; headcount not quantified. Aggregate consideration for the three mid-2011 acquisitions approximately $453M.
2011-06-30divestiture_reductioncompleted2011-01-18Fremont, California, United StatesManufacturingUSD 118 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Boehringer Ingelheim acquired rights and substantially all assets at the Fremont manufacturing operations (closed March 2011); BI assumed facility lease obligations and will manufacture Vectibix for Amgen through 2012. Related $118M write-off of an incomplete manufacturing line recorded in Q4 2010; incremental depreciation and lease-related charges of ~$21M and ~$23M respectively in H1 2011. Employee headcount impact not quantified.
2011-06-30acquisition_additioncompleted2011-03-042011-03-04United StatesHuman therapeutics (R&D)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		BioVex became a wholly owned subsidiary and its operations were consolidated from the acquisition date; no employee headcount disclosed. Total consideration $597 million.
2011-06-30acquisition_additioncompleted2011-04-072011-04-07BrazilPharmaceutical commercial operationsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Laboratorio Quimico Farmaceutico Bergamo Ltda; no employee headcount disclosed.
2011-06-30acquisition_additioncompleted2011-05-162011-05-16IrelandManufacturingbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired Dun Laoghaire manufacturing facility from Pfizer; most facility staff became Amgen employees, but no headcount figure disclosed.
2011-06-30acquisition_additioncompleted2011-06-152011-06-15BrazilPharmaceutical commercial operationsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Reacquired rights to distribute certain products in Brazil upon acquiring business operations from Hypermarcas; no employee headcount disclosed.
2011-06-30divestiture_reductioncompleted2011-01-182011-03-31United States (Fremont, California)Manufacturingother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement with Boehringer Ingelheim to acquire rights and substantially all Fremont assets, closed March 2011; no employee count disclosed. Assets remain on Amgen's balance sheet; BI assumed facility lease obligations and will manufacture Vectibix for Amgen through 2012-12-31. Related charges recorded in cost of sales.
2011-06-30acquisition_additioncompleted2011-03-04United StatesResearch and Developmentbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired BioVex Group, Inc. on March 4, 2011. Most staff became Amgen employees. Specific headcount not disclosed.
2011-06-30acquisition_additioncompleted2011-04-07BrazilSales & Marketingbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Laboratorio Quimico Farmaceutico Bergamo Ltda (Bergamo) on April 7, 2011. Specific headcount not disclosed.
2011-06-30acquisition_additioncompleted2011-05-16IrelandManufacturingbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired manufacturing facility in Dun Laoghaire from Pfizer on May 16, 2011. Most staff became Amgen employees. Specific headcount not disclosed.
2011-06-30acquisition_additioncompleted2011-06-15BrazilSales & Marketingbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reacquired rights to distribute products in Brazil via acquisition of operations from Hypermarcas on June 15, 2011. Specific headcount not disclosed.
2011-03-31acquisition_additioncompleted2011-01-242011-03-04United States / United KingdomOncology R&D (OncoVEXGM-CSF)USD 597 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		BioVex employees became Amgen employees upon acquisition; $7 million paid to settle unvested employee options expensed at acquisition date. No headcount figure disclosed.
2011-03-31acquisition_additionannounced4002011-04BrazilHospital-sector pharmaceuticals / oncology medicinesUSD 215 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Laboratorio Quimico Farmaceutico Bergamo Ltda for approximately $215 million in cash; company has approximately 400 staff, marketed products and manufacturing facilities in Sao Paulo state.
2011-03-31divestiture_reductioncompleted2011-01-182011-03Fremont, California, United StatesManufacturing operationsUSD 21 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Boehringer Ingelheim acquired rights and substantially all assets at Fremont manufacturing operations; transaction did not qualify as a sale so assets remain on balance sheet. Q1 2011 charges: ~$10 million incremental depreciation and ~$11 million lease-related charge in cost of sales. A $118 million write-off of an incomplete manufacturing line was recorded in Q4 2010. No employee headcount disclosed.
2011-03-31acquisition_additioncompleted2011-03-042011-03-04United StatesHuman therapeutics (R&D — OncoVEX GM-CSF program)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		BioVex Group, Inc. acquired for $597M total consideration ($407M cash plus $190M contingent consideration fair value); no employee headcount disclosed. Some BioVex employees became Amgen employees, including $7M paid to settle unvested options.
2011-03-31plant_closurecompleted2011-01-182011-03-31United States (Fremont, California)Manufacturingother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement with Boehringer Ingelheim to acquire rights and substantially all assets at Fremont facility; closed March 2011. No employee count disclosed. Related charges: $10M incremental depreciation and $11M lease charge in Q1 2011 cost of sales; $118M asset write-off recorded in Q4 2010.
2011-03-31acquisition_additioncompleted2011-03-04USD 597 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired BioVex Group, Inc. on March 4, 2011. Total consideration was $597 million. Employee headcount added is not explicitly disclosed.
2011-03-31restructuringcompleted2011-01-18Fremont, CaliforniaManufacturingUSD 21 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Agreement to sell Fremont manufacturing operations to Boehringer Ingelheim closed in March 2011. Recorded $10 million incremental depreciation and $11 million lease charge in Q1 2011. Employee count affected is not disclosed.
2010-12-31divestiture_reductionannounced2011-01-182011-03United States — Fremont, CaliforniaManufacturingUSD 118 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Agreement for Boehringer Ingelheim to acquire Amgen's rights in and substantially all assets of the Fremont manufacturing operations; BI assumes the facility lease obligations and will manufacture Vectibix for Amgen through December 31, 2012. Board approval occurred in December 2010, the impairment was recorded as of December 31, 2010, and closing was anticipated in March 2011. Headcount impact was not quantified. The $118 million charge is an asset impairment (write-off of an incomplete manufacturing line) recorded in 2010 Other charges, not severance.
2010-12-31acquisition_additionannounced2011-01-242011-03Oncology R&D (OncoVEXGM-CSF oncolytic vaccine)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Agreement to acquire BioVex Group, Inc., a privately held biotechnology company developing an oncolytic vaccine in phase 3 trials for melanoma and head and neck cancer; upfront payment of $425 million plus up to $575 million contingent on regulatory and sales milestones. The number of employees to be added was not disclosed; closing was expected during the three months ended March 31, 2011.
2010-12-31plant_closureannounced2011-01-182011-03-31United States — Fremont, CaliforniaManufacturingUSD 118 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement for Boehringer Ingelheim to acquire substantially all Fremont assets; $118M impairment of an incomplete manufacturing line recorded in FY2010 Other charges. Remaining assets of ~$133M deemed recoverable. No employee count disclosed; BI will assume facility lease obligations and manufacture Vectibix through 2012-12-31.
2010-12-31acquisition_additionannounced2011-01-242011-03-31United StatesOncology research and developmentUSD 425 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire BioVex Group, Inc.; $425M upfront plus up to $575M in contingent regulatory and sales milestones for OncoVEX-GM-CSF. No headcount disclosed for the acquired entity.
2010-12-31restructuringcompleted2007-08-152009-12-31WorldwideVariousUSD 70 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		2007 restructuring plan. Completed all actions by Dec 31, 2009. $70M charges recorded in 2009 (primarily staff separation costs of $25M and integration costs of $32M). No specific employee count disclosed for 2009 activity.
2009-12-31restructuringcompleted3,1002007-08-152009-12-31WorldwideWorldwide operations — worldwide staff reductions, rationalization of manufacturing network (including accelerated closure of an ENBREL bulk manufacturing operation in Rhode Island), changes to R&D capital projects, abandonment of leases for R&D and other facilities, and outsourcing of non-core functions including IT infrastructure servicesUSD 957 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Cumulative through fiscal year-end 2009: $957 million of costs, including $213 million of separation costs associated with approximately 3,100 staff members, $476 million asset impairments, $148 million accelerated depreciation and $120 million other net charges. Program announced August 15, 2007 in response to ESA regulatory and reimbursement developments; the filing states all actions were completed and all costs incurred as of December 31, 2009. FY2009 restructuring charges were $70 million ($44 million net of tax), including $30 million of staff separation costs. Restructuring reserves of $133 million remained at December 31, 2009, substantially all for lease payments over 14 years.
2009-12-31restructuringcompleted3,1002007-08-152009-12-31WorldwideCompany-wide (staff reductions, manufacturing network rationalization, facility lease abandonments)USD 70 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative through fiscal year-end since program announced 2007-08-15: approximately 3,100 staff members separated with $213M cumulative separation costs; 2009-only restructuring charges were $70M ($44M net of tax), including $30M of staff separation costs. Filer states all planned actions and related costs were completed by 2009-12-31.
2009-12-31restructuringcompleted3,1002007-08-152009-12-31WorldwideAll functionsUSD 957 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Cumulative costs incurred through Dec 31, 2009 for plan announced Aug 2007. Includes separation costs for approx 3,100 staff members. Plan completed as of fiscal year-end.
2009-09-30restructuringcompleted2007-08-15WorldwideCompany-wide, including manufacturing network rationalization, R&D capital projects, and non-core function outsourcingUSD 952 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2007 restructuring plan driven by regulatory and reimbursement developments affecting ESA products; included worldwide staff reductions, manufacturing facility rationalization, and lease abandonments. Company states all actions substantially completed and all related costs incurred as of September 30, 2009. Cumulative charges of $952 million include $214 million separation costs, $476 million asset impairments, $148 million accelerated depreciation, and $114 million other net charges. No employee count disclosed in this filing.
2009-09-30restructuringcompleted2007-08-152009-09-30WorldwideWorldwide operations (staff reductions, manufacturing network rationalization, abandoned R&D leases)USD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced August 2007; filing states all planned actions and related costs were substantially completed by 2009-09-30, with $952 million cumulative costs incurred through that date ($10 million charged in Q3 2009; $65 million in the nine months then ended). No number of employees affected is disclosed anywhere in the filing.
2009-09-30restructuringcompleted2007-08-15WorldwideVarious (R&D, SG&A, Manufacturing)USD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Company announced restructuring plan on Aug 15, 2007. As of Sept 30, 2009, substantially completed all actions. Q3 2009 charges included $3M asset impairments, $6M SG&A other charges, and $1M other charges. Total cumulative costs incurred through Sept 30, 2009 were $952M.
2009-06-30restructuringin_progress2007-08-15WorldwideCompany-wide (staff reductions, manufacturing network rationalization, lease abandonments, outsourcing of non-core functions)USD 942 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2007 restructuring plan driven by ESA regulatory/reimbursement developments; initial actions completed as of March 31, 2009. Cumulative costs of $942 million incurred through June 30, 2009, including $217 million separation costs, $473 million asset impairments, $148 million accelerated depreciation and $104 million other net charges. Additional $15-$30 million of costs estimated for subsequently identified initiatives. No employee counts disclosed in this filing.
2009-06-30restructuringin_progress2007-08-15WorldwideWorldwide operationsUSD 36 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2009 charges of $36M ($55M YTD), including $29M separation costs ($34M YTD). Initial plan actions completed by 2009-03-31; $15M–$30M of additional costs remain for subsequently identified initiatives. No employee counts disclosed.
2009-06-30othercompletedUnited StatesCorporate — revolving credit facilityother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Lehman subsidiary lender removed from $2.3B credit facility; commitment reduced from $2.5B. Not a workforce action per se — excluded from primary extraction; no employee impact disclosed.
2009-06-30restructuringin_progress2007-08-15WorldwideVarious (Staff reductions, manufacturing rationalization, lease abandonments)USD 36 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 2009 charges of $36M ($24M separation, $6M asset impairment, $6M other). Total costs incurred through June 30, 2009 were $942M. Employee count affected not disclosed.
2009-06-30restructuringin_progress2007-08-15WorldwideVarious (Subsequent initiatives: outsourcing, lease abandonments)USD 55 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2009 charges of $55M ($29M separation, $6M asset impairment, $20M other). Company estimates additional costs of $15M-$30M for subsequent initiatives. Employee count affected not disclosed.
2009-03-31restructuringin_progress2007-08-15WorldwideCompany-wide (staff reductions, manufacturing network rationalization, lease abandonments, outsourcing of non-core functions)USD 19 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2007 restructuring plan; initial actions completed through Q1 2009 with $906M cumulative costs. Q1 2009 charges of $19M comprised $5M separation costs and $14M other. Estimated $45M-$90M of additional costs remain for subsequently identified initiatives. No employee counts disclosed in this filing.
2009-03-31restructuringin_progress2007-08-15WorldwideWorldwide operations (staff reductions, manufacturing network rationalization, lease abandonments)USD 19 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2009 charges of $19M ($5M separation, $14M other); cumulative $906M through 2009-03-31; $45M–$90M of additional costs estimated for subsequently identified initiatives; no employee headcount disclosed
2009-03-31restructuringin_progress2007-08-15WorldwideVarious (Staff, Manufacturing, R&D)USD 19 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q1 2009 charges of $19M ($5M separation, $14M other). Initial plan completed; subsequent initiatives estimated at $45M-$90M remaining.
2008-12-31restructuringcompleted2,5002007-08-152008-12-31WorldwideAll functions — staff reductions, manufacturing network rationalization, and facility lease actionsUSD 148 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Worldwide plan announced 2007-08-15 with components of approximately 2,500 position reductions, rationalization of the worldwide manufacturing network (including accelerated closure of an ENBREL bulk manufacturing operation, closure of a clinical manufacturing facility in Thousand Oaks, and indefinite postponement of planned Ireland operations), and abandonment of leases primarily for R&D facilities no longer used. Staff reduction was executed via a voluntary transition program plus an involuntary reduction in force and was completed by fiscal year-end 2008; substantially all plan actions were complete through 2008-12-31, with remaining costs expected to be substantially incurred in 2009. Associated charge shown is the fiscal 2008 restructuring charge of $148 million ($111 million net of tax). Cumulative plan charges through 2008-12-31 were $887 million against a total plan estimate of $950 million to $985 million, raised from a prior estimate of $775 million to $825 million to include 2008 additional initiatives (outsourcing of non-core functions, notably information systems infrastructure services, and further lease abandonments) estimated at $95 million to $135 million. Amounts are net of cost recoveries from ENBREL co-promotion partner Wyeth. Headcount figure is the cumulative plan-level target, not a fiscal-2008-only count.
2008-12-31divestiture_reductioncompleted2008-09GlobalSupportive cancer care and inflammation marketed products (Kepivance, Stemgen, Kineret license)USD 10 (millions)MD&A
f5-10k / GLM-5.3-flash-HTML		Biovitrum AB acquired the marketed biologics Kepivance (palifermin) and Stemgen (ancestim) and obtained a worldwide exclusive license to Kineret (anakinra) for its approved indication; the disposal of these less significant marketed products formed part of the restructuring plan. A $10 million loss on disposal was recorded in Interest and other income, net. Worldwide 2008 product sales of the divested products were approximately $70 million. Employee headcount transfer or reduction was not disclosed; exact completion date within fiscal 2008 not specified.
2008-12-31divestiture_reductioncompleted2008-02JapanJapan commercial subsidiary (Amgen K.K.)Item_1_Business
f5-10k / GLM-5.3-flash-HTML		In connection with February 2008 license and collaboration agreements with Takeda Pharmaceutical Company Limited, Takeda acquired Amgen's Japanese subsidiary Amgen K.K. and received exclusive Japanese rights to up to 12 clinical-stage molecules, with Amgen retaining the right to participate in Japanese promotion. Headcount removed from the consolidated workforce through this subsidiary divestiture was not disclosed; exact completion date within fiscal 2008 not specified.
2008-12-31acquisition_additioncompleted2008-01-042008-01-04ItalyItalian commercial operations (Dompé Biotec, S.p.A.)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Amgen acquired the remaining 51% ownership interest of Dompé Biotec, S.p.A. (49% previously held and equity-method accounted); purchase price approximately $168 million including the carrying value of the existing 49% stake, with approximately $105 million assigned to goodwill; cash paid net of cash acquired was $56 million. Headcount added to the consolidated workforce through this business combination was not disclosed. Announcement date reflects the acquisition completion date; separate agreement announcement date not disclosed.
2008-12-31restructuringcompleted2,5002007-08-152009-12-31WorldwideCompany-wideUSD 148 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative program figure: approximately 2,500 worldwide staff reduction positions since the August 2007 announcement; substantially all initially planned actions completed through 2008-12-31. Charge shown is FY2008 restructuring charges of $148M; cumulative charges incurred through 2008-12-31 were $887M against a total program estimate of $950M-$985M, with remaining costs expected to be incurred through 2009. Program also included manufacturing network rationalization and lease abandonments.
2008-12-31restructuringin_progress2008-12-312009-12-31WorldwideInformation systems and facilitiesUSD 115 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Additional cost-structure initiatives identified during 2008, including outsourcing of information systems infrastructure services (IBM Master Services Agreement dated 2008-10-22) and abandonment of additional facility leases. Estimated cost range disclosed as $95M to $135M; midpoint shown. No employee-impact count disclosed.
2008-12-31divestiture_reductioncompleted2008-09-30WorldwideMarketed products (Kepivance, Stemgen, Kineret license)USD 10 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		September 2008 agreement with Biovitrum AB covering divestiture of Kepivance and Stemgen and an exclusive worldwide license to Kineret; $10M loss recorded. Divested products had approximately $70M of 2008 worldwide sales. No headcount impact disclosed; exact announcement day not specified.
2008-12-31acquisition_additioncompleted2008-01-042008-01-04ItalyCommercial operationsUSD 168 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of the remaining 51% of Dompé Biotec completed 2008-01-04; purchase price approximately $168M including the existing 49% stake. No employee headcount added through the acquisition is disclosed.
2008-12-31restructuringin_progress2,5002007-08-152009-12-31WorldwideVariousUSD 968 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Announced Aug 2007. Initial estimate $775-825M increased to $950-985M in 2008. Includes staff reductions of approx 2,500 positions, manufacturing rationalization, and lease abandonments. $887M incurred through Dec 31, 2008; remainder expected through 2009.
2008-09-30restructuringin_progress2,5002007-08-152009-12-31WorldwideCompany-wide (manufacturing network rationalization, R&D capital projects, lease abandonment)USD 790 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan announced August 15, 2007 in response to ESA regulatory/reimbursement developments; approximately 2,500 positions to be eliminated. $790 million of charges incurred through September 30, 2008; total expected charges raised to $850-$925 million (from prior $775-$825 million estimate), with remaining costs expected through 2009. Amounts are net of recoveries from co-promotion partner Wyeth. Majority of actions completed as of September 30, 2008.
2008-09-30restructuringannounced2008-09-302009-12-31Non-core business functions (information systems infrastructure services outsourcing); additional facility lease abandonmentrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Recently identified additional initiatives to further improve cost structure, including outsourcing certain information systems infrastructure services and abandoning leases for additional facilities; estimated cost of $50-$100 million, included in the raised total program estimate of $850-$925 million.
2008-09-30divestiture_reductionannounced2008-09-15Marketed products Kepivance, Stemgen and Kineret licenseUSD 9 (millions)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Agreement for Biovitrum AB to acquire Kepivance and Stemgen and obtain worldwide exclusive license to Kineret; $9 million loss accrual on disposal recorded in Q3 2008 in Interest and other income and (expense), net. No employee headcount figures disclosed.
2008-09-30acquisition_additioncompleted2008-01-042008-01-04ItalyDompé Biotec, S.p.A.USD 162 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of remaining 51% ownership interest of Dompé on January 4, 2008 for approximately $162 million including existing 49% stake; no employee headcount figures disclosed.
2008-09-30restructuringin_progress2,5002007-08-152009-12-31WorldwideCompany-wide (staff reductions, manufacturing network rationalization, R&D lease abandonments)USD 790 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 2,500 positions targeted; $790M incurred through 2008-09-30 of an expected $850M-$925M total (raised from prior $775M-$825M estimate); remaining costs expected through 2009; amounts net of Wyeth cost recoveries
2008-09-30restructuringannounced2009-12-31WorldwideNon-core business functions, notably information systems infrastructure services; additional facility lease abandonmentsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Additional initiatives identified during the quarter, estimated cost $50M to $100M; implementation includes an outsourcing agreement with IBM entered 2008-10-22 (five-year term, ~$500M); no employee count disclosed
2008-09-30restructuringin_progress2,5002007-08-152009-12-31WorldwideGlobal OperationsUSD 790 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Initial plan announced Aug 2007 included ~2,500 staff reductions. Through Sept 30, 2008, $790M incurred. Total expected charges increased to $850M-$925M including additional initiatives. Remaining costs expected through 2009.
2008-06-30restructuringin_progress2,5002007-08-152008-12-31WorldwideCompany-wide; manufacturing facility rationalization, R&D capital project changes, lease abandonmentsUSD 773 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan announced August 15, 2007; approximately 2,500 positions to be eliminated. Through June 30, 2008, $773 million of the estimated $775-$825 million total charges incurred, comprising $185 million separation costs, $423 million asset impairments, $148 million accelerated depreciation and $17 million other charges (including $132 million lease loss accruals offset by $115 million Wyeth cost recoveries). Majority of actions completed; remaining actions expected to be substantially completed in 2008.
2008-06-30restructuringin_progress2,5002007-08-152008-12-31WorldwideWorldwide operations (staff reductions, manufacturing network rationalization, R&D lease abandonments)USD 800 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Estimated total charge range of $775M to $825M; $773M incurred through June 30, 2008. Approximately 2,500 positions targeted for reduction. Majority of actions completed through June 30, 2008; remaining actions expected substantially complete during 2008. Charges are net of amounts recoverable from Wyeth.
2008-06-30acquisition_additioncompleted2008-01-042008-01-04ItalyCommercial (marketing of Amgen products in Italy)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining 51% of Dompé Biotec completed January 4, 2008; purchase price approximately $162M. No headcount added disclosed.
2008-06-30restructuringin_progress2,5002007-08-152008-12-31WorldwideWorldwide operationsUSD 773 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan announced Aug 15, 2007 to improve cost structure. Includes worldwide staff reductions of approx 2,500 positions, rationalization of manufacturing facilities, and lease abandonments. $773M incurred through June 30, 2008 of estimated $775M-$825M total. Expected substantially completed in 2008.
2008-03-31restructuringin_progress2,5002007-08-152008-12-31WorldwideCompany-wide; manufacturing network rationalization, R&D capital projects, and lease abandonment for certain R&D facilitiesUSD 751 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan announced August 15, 2007 in response to ESA regulatory and reimbursement developments. Approximately 2,500 positions to be eliminated worldwide. Estimated total charges of $775-$825 million, of which $751 million incurred through March 31, 2008 (including $184 million separation costs, $411 million asset impairments, $148 million accelerated depreciation, and $8 million other charges, net of Wyeth cost recoveries). Majority of actions completed through March 31, 2008; remaining actions expected to be substantially completed in 2008. Q1 2008 charges of $12 million recorded across cost of sales ($1M), R&D ($2M), SG&A (-$1M), and Other ($10M). Restructuring reserves of $127 million as of March 31, 2008.
2008-03-31restructuringin_progress2,5002007-08-152008-12-31WorldwideWorldwide operations; includes manufacturing network rationalization and abandonment of certain R&D facility leasesUSD 751 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative charges incurred through 2008-03-31 of an estimated $775M–$825M total; includes ~2,500 staff positions plus asset impairments and accelerated depreciation. A majority of actions completed through quarter-end; remainder expected substantially complete in 2008. Filer states a majority of actions were completed through 2008-03-31 but does not disclose a count of positions eliminated in the current quarter.
2008-03-31acquisition_additioncompleted2008-01-042008-01-04ItalyCommercial operations (marketing of Amgen products in Italy)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining 51% of Dompé Biotec, S.p.A. completed 2008-01-04 for ~$162M purchase price; no headcount added disclosed.
2008-03-31restructuringin_progress2,5002007-08-152008-12-31WorldwideWorldwide operationsUSD 751 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan announced Aug 15, 2007 to improve cost structure. Includes worldwide staff reductions of approx 2,500 positions, rationalization of manufacturing facilities, and abandoning leases. $751M incurred through Mar 31, 2008 of estimated $775M-$825M total. Expect remaining actions substantially completed in 2008.
2007-12-31restructuringin_progress2,20012%2007-08-152008WorldwideCompany-wide: staff reductions across all functions, plus rationalization of the worldwide manufacturing network and abandonment of leases for certain R&D facilitiesUSD 739 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Worldwide restructuring plan announced 2007-08-15. Staff reductions of approximately 2,200 to 2,600 positions, or approximately 12% to 14% of worldwide staff (values shown are lower bounds of disclosed ranges), executed through a voluntary transition program and an involuntary reduction in force. Program also included rationalization of the worldwide manufacturing network — accelerated closure of an ENBREL bulk manufacturing operation in West Greenwich, Rhode Island, closure of a clinical manufacturing facility in Thousand Oaks, California, indefinite postponement of planned Ireland manufacturing operations and revisions to the planned Puerto Rico manufacturing expansion — plus loss accruals for abandoned R&D facility leases. Estimated total charges of $775 million to $825 million; $739 million incurred through 2007-12-31, net of $114 million of recoveries from co-promotion partner Wyeth, including $209 million of staff separation costs. Majority of actions completed in 2007; substantially all remaining actions and estimated costs expected in 2008. Implied workforce size from the disclosed percentage range is roughly consistent with the ~17,500 total staff.
2007-12-31acquisition_additioncompleted2007-07-16business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Alantos Pharmaceuticals Holding, Inc. completed July 16, 2007 (completion date used as action date) for cash of approximately $300 million; privately held diabetes/inflammatory-disease developer. Headcount added through the business combination was not disclosed.
2007-12-31acquisition_additioncompleted2007-07-18business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Ilypsa, Inc. completed July 18, 2007 (completion date used as action date) for cash of approximately $400 million; privately held developer of non-absorbed drugs for renal disorders. Headcount added through the business combination was not disclosed.
2007-12-31acquisition_additioncompletedUSD 21 (millions)other
f5-10k / GLM-5.3-flash-HTML		Severance-related expenses of $21 million ($13 million net of tax) incurred in the fourth quarter of 2007 in connection with the acquisition of the remaining 51% ownership interest of Dompe Biotec, S.p.A.; headcount affected not disclosed.
2007-12-31divestiture_reductionannounced2008-02JapanMD&A
f5-10k / GLM-5.3-flash-HTML		In connection with February 2008 license and collaboration agreements with Takeda Pharmaceutical Company Limited, Takeda agreed to acquire Amgen K.K., Amgen's subsidiary in Japan; employees transferring out of the consolidated workforce were not quantified. Disclosed as a subsequent event relative to fiscal year-end 2007.
2007-12-31restructuringin_progress2007-08-152008-12-31WorldwideCompany-wide (worldwide operations)USD 739 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Planned staff reductions of approximately 2,200 to 2,600 positions, or approximately 12% to 14% of worldwide staff; total estimated charges of $775 million to $825 million, of which $739 million was incurred through December 31, 2007. Program includes manufacturing network rationalization (indefinite postponement of planned Ireland operations, revisions to Puerto Rico expansion, accelerated closure of an ENBREL bulk manufacturing operation in West Greenwich, Rhode Island, and closure of a clinical manufacturing facility in Thousand Oaks, California) plus abandonment of certain R&D leases; remaining actions expected to be completed in 2008.
2007-12-31acquisition_additioncompleted2007-07-162007-07-16United StatesResearch and Development (diabetes and inflammatory disease programs)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition completed July 16, 2007 for approximately $300 million cash; acquired headcount not disclosed in the filing.
2007-12-31acquisition_additioncompleted2007-07-182007-07-18United StatesResearch and Development (renal disorders programs)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition completed July 18, 2007 for approximately $400 million cash; acquired headcount not disclosed in the filing.
2007-12-31divestiture_reductionannounced2008-02JapanCountry subsidiary (Amgen K.K.)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Subsequent event: in February 2008 Takeda agreed to acquire Amgen's Japanese subsidiary Amgen K.K. in connection with licensing and collaboration agreements; affected headcount not disclosed. Filing also notes leased facilities in Japan will be disposed of in connection with this transaction.
2007-12-31restructuringin_progress2,40013%2007-08-152008-12-31WorldwideAll functionsUSD 800 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Announced plan to reduce staff by approximately 2,200 to 2,600 positions (approx. 12-14% of worldwide staff). Estimated total charges $775M-$825M; $739M incurred through Dec 31, 2007. Includes staff reductions, manufacturing rationalization, and lease abandonments.
2007-09-30restructuringin_progress2007-08-152008-12-31WorldwideAll functionsrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Staff reduction of approximately 2,200 to 2,600 positions (12% to 14% of staff) with severance charges of approximately $200 million to $230 million; total program charges estimated at $775 million to $850 million, net of amounts recoverable from co-promotion partner Wyeth. Remaining costs expected in Q4 2007 and to a lesser degree in 2008.
2007-09-30restructuringin_progress2007-08-152008-12-31WorldwideManufacturingrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Re-scoping of capital projects and closure of certain production operations to rationalize the worldwide manufacturing network; expected charges of approximately $470 million to $490 million, primarily asset impairments and accelerated depreciation.
2007-09-30plant_closurein_progress2007-08-15IrelandManufacturingrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Indefinite postponement of planned Ireland manufacturing operations; contributed to the increase in total estimated restructuring charges from $600-$700 million to $775-$850 million.
2007-09-30plant_closurein_progress2007-08-15Thousand Oaks, CaliforniaClinical manufacturingrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Closure of a clinical manufacturing facility in Thousand Oaks; contributed to the increase in total estimated restructuring charges.
2007-09-30plant_closurein_progress2007-08-15United StatesENBREL commercial bulk manufacturingUSD 110 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Accelerated closure of one ENBREL commercial bulk manufacturing operation; assets lack alternative future uses but cash flows recover book value, so $110 million of excess accelerated depreciation was recorded in cost of sales rather than an immediate impairment.
2007-09-30restructuringin_progress2007-08-152008-12-31WorldwideWorldwide operations (all functions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Staff reduction of approximately 12% to 14%, or approximately 2,200 to 2,600 positions (disclosed as a range; no single count stated). Severance-related restructuring charges estimated at $200 million to $230 million (range). Driven by 2007 regulatory and reimbursement developments for ESA products (Aranesp, EPOGEN). Severance accrued in the quarter: $104 million; year to date: $107 million. Remaining actions expected to be substantially completed by 2008; remaining costs expected mainly in Q4 2007 and, to a lesser degree, 2008. Approximately 50% of total estimated plan charges will result in cash outlays, primarily staff separation costs through 2008.
2007-09-30plant_closurein_progress2007-08-152008-12-31Worldwide (including Ireland and Thousand Oaks, California, USA)Manufacturing and research facilitiesrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Manufacturing network rationalization component of the same 2007-08-15 plan: indefinite postponement of Ireland manufacturing operations, revisions to Puerto Rico expansion, accelerated closure of one ENBREL commercial bulk manufacturing operation, and closure of a clinical manufacturing facility in Thousand Oaks. Related charges estimated at $470 million to $490 million (range), primarily asset impairments plus accelerated depreciation; no employee count disclosed for this component. Asset impairments recorded: $286 million in Q2 2007 and an additional $110 million in Q3 2007; accelerated depreciation excess of $110 million in cost of sales. A further $105 million to $130 million (range) of other charges relates to lease loss accruals for unused R&D facilities. Total plan charges estimated at $775 million to $850 million (range), net of amounts recoverable from Wyeth.
2007-09-30acquisition_additioncompleted2007-07-162007-07-16United StatesResearch & Development (diabetes and inflammatory diseases)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Alantos Pharmaceuticals Holding, Inc. completed 2007-07-16 for approximately $300 million cash; operations consolidated from that date. No employee headcount added disclosed. Related $270 million IPR&D write-off recorded in Q3 2007.
2007-09-30acquisition_additioncompleted2007-07-182007-07-18United StatesResearch & Development (renal disorders)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Ilypsa, Inc. completed 2007-07-18 for approximately $400 million cash; operations consolidated from that date. No employee headcount added disclosed. Related $320 million IPR&D write-off recorded in Q3 2007.
2007-09-30restructuringin_progress2007-08-152008-12-31WorldwideAll functionsUSD 775 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan announced Aug 15, 2007 to reduce staff by approx 2,200-2,600 positions (12-14%). Total estimated charges $775M-$850M. Includes staff separation, asset impairments, accelerated depreciation, and lease losses. Majority of actions initiated; remaining expected substantially completed by 2008.
2007-06-30restructuringin_progress2007-06-30WorldwideManufacturing and research facilitiesUSD 289 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global business-plan review to improve cost structure amid ESA product challenges; includes re-scoping of Ireland manufacturing operations, revisions to Puerto Rico expansion, and moderated research facility expansion. Charge comprises $286M asset impairment plus $3M related costs. No employee count, severance detail, or announcement date disclosed; date shown is quarter-end. Filer warns additional charges may follow.
2007-06-30acquisition_additioncompleted2007-07-162007-07-16United StatesResearch and development (diabetes and inflammatory diseases)USD 300 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cash acquisition consideration of approximately $300 million; no headcount added disclosed. IPR&D write-off expected in Q3 2007.
2007-06-30acquisition_additioncompleted2007-07-182007-07-18United StatesResearch and development (renal disorders)USD 420 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cash acquisition consideration of approximately $420 million; no headcount added disclosed. IPR&D write-off expected in Q3 2007.
2007-06-30restructuringcompleted2007-06-30GlobalManufacturing and ResearchUSD 289 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Company recorded charges for asset impairment of $286 million and related costs of $3 million due to rationalizing worldwide network of manufacturing facilities and moderating expansion of research facilities. Employee count not disclosed.
2007-06-30acquisition_additioncompleted2007-07-16USD 300 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Completed acquisition of Alantos Pharmaceutical Holding, Inc. for approximately $300 million cash. Employee count not disclosed.
2007-06-30acquisition_additioncompleted2007-07-18USD 420 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Completed acquisition of Ilypsa, Inc. for approximately $420 million cash. Employee count not disclosed.
2006-12-31acquisition_additioncompleted2006-04-01USD 2,200 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired all outstanding common stock of Abgenix, a monoclonal antibody discovery and development company, for approximately $2.2 billion. Employee headcount added through the acquisition is not disclosed.
2006-12-31acquisition_additioncompleted2006-10-24USD 275 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired privately held Avidia, Inc., a developer of Avimer protein therapeutics, for approximately $275 million net of cash acquired and existing equity stake. Employee headcount added through the acquisition is not disclosed.
2006-12-31acquisition_additioncompleted2006-04-012006-04-01United StatesResearch and developmentUSD 1,101 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Abgenix completed April 1, 2006 for approximately $2.2 billion; acquired headcount not disclosed. Associated charge is the $1,101 million write-off of acquired in-process R&D, not a severance cost.
2006-12-31acquisition_additioncompleted2006-10-242006-10-24United StatesResearch and developmentUSD 130 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Avidia completed October 24, 2006 for approximately $275 million net of cash; acquired headcount not disclosed. Associated charge is the $130 million write-off of acquired in-process R&D, not a severance cost.
2006-09-30acquisition_additioncompleted2006-04-01United StatesHuman therapeutic antibodies (Abgenix, Inc.)USD 2,195 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired all outstanding Abgenix common stock for $22.50 per share in cash; also assumed 1.9 million stock options (1.4 million vested) and assumed convertible debt later repaid. No employee headcount figures disclosed.
2006-09-30acquisition_additionannounced2006-10-24United StatesAvimer proteins; IL-6 inhibitor program (Avidia, Inc.)USD 290 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Completed acquisition of privately held Avidia for approximately $290 million cash net of cash acquired and existing equity stake; acquired IPR&D to be expensed in Q4 2006. No employee headcount figures disclosed.
2006-09-30acquisition_additioncompleted2006-04-012006-04-01United StatesHuman therapeutics (R&D / antibody discovery)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Abgenix completed April 1, 2006; results included from that date. No employee headcount added was disclosed.
2006-09-30acquisition_additionannounced2006-10-242006-10-24United StatesHuman therapeutics (R&D)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Avidia, Inc. acquisition completed October 24, 2006 (post-quarter); cash consideration approx. $290 million net. No employee headcount added was disclosed.
2006-09-30acquisition_additioncompleted2006-04-01business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Abgenix on April 1, 2006. Headcount not disclosed, but 1.9 million stock options were issued in exchange for assumed options.
2006-09-30acquisition_additionannounced2006-10-24subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Completed acquisition of Avidia, Inc. on October 24, 2006. Headcount not disclosed.
2006-06-30acquisition_additioncompleted2006-04-012006-04-01United StatesHuman therapeuticsUSD 2,195 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Amgen acquired all outstanding Abgenix common stock on April 1, 2006 for $22.50 per share (~$2.1 billion cash) plus assumed debt; total purchase price $2,195 million. Headcount added through the acquisition is not quantified in the filing. Abgenix stock options (1.9 million, of which 1.4 million vested) were assumed.
2006-06-30acquisition_additioncompleted2006-04-012006-04-01United StatesHuman therapeutics (single reportable segment)USD 1,101 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Abgenix completed 2006-04-01 for $2,195M total consideration; no employee headcount added disclosed. $1,101M of acquired in-process R&D expensed; 1.9M Abgenix stock options assumed (1.4M vested).
2006-06-30acquisition_additioncompleted2006-04-01business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Abgenix on April 1, 2006. Specific headcount added not disclosed in this filing.
2006-06-30otherannounced1,0002006-06-302006-12-31Research and DevelopmentMD&A
f5-10q / Qwen3.6-27B-Q8_0		Planned hiring of approximately 1,000 new staff into R&D organizations in 2006.
2006-03-31acquisition_additioncompleted2005-12-012006-04-01United StatesHuman therapeutic antibodies (panitumumab co-development partner)USD 2,100 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Abgenix completed April 1, 2006 for approximately $2.1 billion cash plus assumption of ~$703 million fair value of debt; no employee headcount figure disclosed. Purchase price allocation not finalized.
2006-03-31acquisition_additioncompleted2005-12-312006-04-01United StatesHuman therapeutics (research, development and manufacturing)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Abgenix, Inc. closed 2006-04-01 for ~$2.1B cash plus ~$703M assumed debt; headcount added not disclosed. In-process R&D write-off expected in Q2 2006.
2005-12-31acquisition_additionannounced2005-122006-04business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Definitive merger agreement signed December 2005: $22.50 per share in cash, total value ~$2.2 billion, plus assumption of Abgenix debt. FTC approval received January 19, 2006; closing expected by April 2006 subject to Abgenix shareholder approval. Transaction not closed as of fiscal year-end or filing date; no headcount figures disclosed for Abgenix.
2005-12-31acquisition_additionannounced2005-12-312006-04-30United StatesResearch and developmentsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definition merger agreement signed in December 2005 to acquire Abgenix for $22.50 per share, total value approximately $2.2 billion plus assumed debt; FTC approved 2006-01-19, closing expected by April 2006 subject to Abgenix shareholder approval. Headcount added not disclosed; an IPR&D write-off charge expected but amount undetermined.
2004-12-31acquisition_additioncompleted2004-08-132004-08-13United StatesResearch and development / drug discoverybusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Tularik Inc., a drug-discovery company, completed August 13, 2004 for approximately $1.5 billion in stock; headcount added was not quantified in the filing. MD&A attributes part of the 2004 R&D staff-cost increase to the addition of R&D personnel from Tularik. The $554 million IPR&D write-off is an acquisition accounting charge, not a severance or restructuring charge.
2004-12-31acquisition_additioncompleted2004-08-132004-08-13United StatesResearch and developmentUSD 554 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Tularik acquired for approximately $1.5 billion; headcount added not quantified. $554 million charge for write-off of acquired in-process R&D. R&D staff-related costs increased approximately $233 million in 2004, including addition of R&D personnel from Tularik.
2004-12-31acquisition_additioncompleted2004-08-132004-08-13GlobalResearch and DevelopmentItem 1. Business - Overview
f5-10k / Qwen3.6-27B-Q8_0		Acquired Tularik Inc. on August 13, 2004. Specific headcount added not disclosed in text, but R&D personnel costs increased due to addition of Tularik staff.
2004-09-30acquisition_additioncompleted2004-08-13Research and Developmentbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Tularik Inc. on August 13, 2004. MD&A notes 'addition of R&D personnel from Tularik' as a driver for increased staff-related costs, but specific headcount is not disclosed.
2004-06-30acquisition_additionannounced2004-03-28USD 2 (billions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Definitive agreement to acquire Tularik Inc. in a stock-based business combination; estimated purchase price approximately $1.5 billion including Amgen's existing ~21% ownership. Expected to close in the second half of 2004 subject to Tularik shareholder approval and regulatory approvals. No headcount figures disclosed.
2003-12-31restructuringin_progress2002-07-15Integration of pre-acquisition Immunex functions and leased facilitiesUSD 96 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Integration plan initiated in connection with the July 15, 2002 Immunex acquisition, involving termination and relocation of certain Immunex personnel and consolidation of certain leased facilities. Approximately $96 million in costs were recognized as liabilities assumed in the purchase business combination (cumulative through fiscal year-end); approximately $30 million remained to be paid as of December 31, 2003. Number of employees affected not disclosed.
2003-12-31restructuringin_progress2002-07-15GlobalVariousUSD 96 (millions)business_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Integration plan to consolidate and restructure certain functions and operations of pre-acquisition Immunex, primarily consisting of termination and relocation of personnel and consolidation of leased facilities. Aggregate costs of approximately $96 million recognized as liabilities assumed in purchase business combination. As of Dec 31, 2003, approximately $30 million remaining to be paid.
2003-09-30restructuringin_progress2002-07-15United StatesImmunex integration — personnel and facilitiesrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Integration plan covering Immunex personnel terminations/relocations and facility consolidation; $32.2M liability remained at 9/30/03 after $23.2M of payments in 2003. No employee counts disclosed.
2003-09-30restructuringin_progress2002-07-15USD 32 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Integration plan to consolidate and restructure certain functions and operations of pre-acquisition Immunex, primarily consisting of termination and relocation of personnel and consolidation of leased facilities. Remaining liability balance as of Sept 30, 2003 was $32.2 million.
2003-06-30restructuringin_progress2002-07-15Integration of pre-acquisition Immunex functions and operationsrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Integration plan to consolidate and restructure certain pre-acquisition Immunex functions, primarily termination and relocation of certain Immunex personnel and consolidation of leased facilities. Liabilities assumed in purchase accounting and reflected as an increase to goodwill. Liability roll-forward at 6/30/03: employee related benefits $9.6M (balance 12/31/02 $24.1M, payments $15.3M); facility consolidation $28.7M (balance 12/31/02 $30.8M, payments $2.1M); total $38.3M. No employee counts disclosed.
2003-06-30restructuringin_progress2002-07-15United StatesImmunex integration — employee-related benefitsUSD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Integration plan initiated with the July 2002 Immunex acquisition; employee-related benefits liability of $9.6M remained at 6/30/03 after $15.3M of payments in the period. No employee count disclosed.
2003-06-30restructuringin_progress2002-07-15United StatesImmunex integration — facility consolidationUSD 29 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Consolidation of certain Immunex leased facilities; liability of $28.7M remained at 6/30/03 after $2.1M of payments in the period. No employee count disclosed.
2003-06-30restructuringin_progress2002-07-15Integration of Immunex CorporationUSD 38 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Liabilities established for integration plan including termination/relocation of personnel and facility consolidation. Balance at June 30, 2003 was $38.3 million ($9.6M employee benefits, $28.7M facility consolidation). Employee count affected is not disclosed.
2003-03-31restructuringin_progress2002-07-15Immunex integration — personnel termination/relocation, R&D program terminations, facility consolidationUSD 55 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Liabilities assumed in purchase combination per EITF 95-3; balance at 12/31/02 of $54.9M ($24.1M employee related benefits, $30.8M facility consolidation); $13.1M paid in Q1 2003, $1.7M adjustment added; remaining balance $43.5M at 3/31/03. No employee counts disclosed.
2003-03-31acquisition_additioncompleted2002-07-152002-07-15United StatesAllUSD 17,772 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Amgen acquired all outstanding Immunex common stock; results included from July 16, 2002. No headcount added disclosed.
2003-03-31restructuringin_progress2002-07-15United StatesCorporate / R&D / FacilitiesUSD 44 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Integration plan includes termination/relocation of Immunex personnel, termination of duplicative R&D programs, and facility consolidation. Remaining liability $43.5M at 3/31/03; no employee count disclosed.
2003-03-31restructuringin_progress2002-07-15Employee related benefitsUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Adjustments to liabilities assumed in purchase business combination for Immunex integration plan.
2003-03-31restructuringin_progress2002-07-15Facility consolidationUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		No adjustments recorded for facility consolidation in Q1 2003.
2002-12-31acquisition_additioncompleted2001-12-162002-07-15United StatesWhole company (Immunex Corporation)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Amgen acquired all outstanding Immunex common stock on July 15, 2002 (merger announced December 16, 2001); each Immunex share converted into 0.44 Amgen shares plus $4.50 cash, with ~244.6 million shares issued and ~$2.5 billion cash paid; total purchase price ~$17.8 billion including a $2,991.8 million acquired IPR&D write-off. Acquired-employee headcount not quantified; ~22.4 million employee stock options assumed and ~150 former Immunex employees placed on transition assignments ending in 2003.
2002-12-31restructuringin_progress2002-07-15United States (former Immunex operations)Former Immunex personnel terminations/relocations, including duplicative R&D program terminationsUSD 65 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Integration plan initiated in connection with the acquisition covering termination and relocation of certain Immunex personnel and termination of duplicative/non-strategic R&D programs. Employee-related-benefits liability of $65.1M established in purchase accounting; $41.0M paid through 12/31/02, leaving a $24.1M balance. Number of employees affected not disclosed.
2002-12-31restructuringin_progress2002-07-15United States (former Immunex leased facilities)Facility consolidationUSD 31 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Facility-consolidation component of the Immunex integration plan; liability of $31.2M established at acquisition, with only $0.4M paid through 12/31/02, leaving a $30.8M balance.
2002-12-31divestiture_reductioncompleted2002-052002-07-17United States (Leukine business)Leukine business assetsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Immunex agreed in May 2002 to sell certain assets of its Leukine business to Schering AG (Germany); sale completed July 17, 2002 for approximately $389.9 million cash plus additional milestone consideration. Workforce impact not quantified.
2002-12-31acquisition_additioncompleted2001-12-162002-07-15United StatesCompany-wide (immunology, inflammation, oncology research and commercial functions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Amgen acquired all outstanding Immunex common stock on 2002-07-15 for approximately $17.8 billion; results consolidated from 2002-07-16. Total acquired headcount not disclosed; approximately 150 former Immunex employees remained on transition assignments as of 2002-12-31, and approximately 22.4 million converted options were assumed.
2002-12-31divestiture_reductioncompleted2002-05-312002-07-17United StatesLeukine (sargramostim) businessbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Immunex agreed in May 2002 to sell Leukine-related assets to Schering AG Germany for approximately $389.9 million cash plus milestone payments; sale completed 2002-07-17 in connection with the Amgen/Immunex merger. Associated headcount not disclosed.
2002-12-31restructuringin_progress2002-07-15United StatesFormer Immunex operations — personnel, duplicative/non-strategic R&D programs, leased facilitiesUSD 96 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Integration plan initiated in connection with the Immunex acquisition: $65.1M employee-related benefits and $31.2M facility consolidation liabilities established as liabilities assumed (recorded as an increase to goodwill); $41.4M paid through 2002-12-31, leaving a $54.9M balance. Employees affected not quantified; program covers termination and relocation of certain Immunex personnel, termination of duplicative and non-strategic Immunex R&D programs, and consolidation of certain Immunex leased facilities. No completion date stated.
2002-12-31othercompleted2002-12-012002-12-31United StatesNovantrone commercialization rightsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		In December 2002 Amgen licensed U.S. commercialization rights for Novantrone to Serono S.A. in exchange for royalties on future sales; associated workforce impact not disclosed.
2002-12-31acquisition_additioncompleted2002-07-152002-07-15GlobalAll FunctionsItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Immunex Corporation completed July 15, 2002. Results included from July 16, 2002. Specific headcount added not disclosed, but 150 employees on transition assignments noted at year-end.
2002-12-31restructuringin_progress2002-07-15GlobalAll FunctionsUSD 96 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Integration plan to consolidate and restructure pre-acquisition Immunex functions. Includes termination/relocation of personnel, termination of R&D programs, and consolidation of leased facilities. Total liability established $96.3 million; $41.4 million paid through Dec 31, 2002. Specific employee count not disclosed.
2002-09-30acquisition_additioncompleted2002-07-152002-07-15United StatesCompany-wide (Immunex Corporation)USD 17,772 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Amgen acquired Immunex on July 15, 2002; total purchase price $17,771.8 million. Immunex employees and approximately 22.4 million assumed stock options were added, but no employee headcount figure is disclosed.
2002-09-30restructuringin_progress2002-07-15Immunex personnel terminations and relocations; consolidation of manufacturing and administrative leased facilitiesUSD 49 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Integration plan to consolidate pre-acquisition Immunex functions: employee terminations and relocations, termination of duplicative R&D programs, facility consolidation. Approximately $48.7 million provided at close for terminations/relocations, of which about $19.3 million was unpaid as of September 30, 2002; recognized as liability assumed and increased goodwill per EITF 95-3. No employee count disclosed; other restructuring plans still being evaluated with no amounts recorded.
2002-09-30divestiture_reductioncompleted2002-05-012002-07-17Leukine businessUSD 390 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Immunex agreed in May 2002 to sell certain Leukine business assets to Schering AG Germany for approximately $389.9 million cash plus milestone consideration; sale completed July 17, 2002. No employee headcount affected is disclosed.
2002-09-30acquisition_additioncompleted2002-07-152002-07-15United StatesCompany-widebusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Immunex results included from July 16, 2002; approximately 244.6 million Amgen shares and about 22.4 million converted options issued, but no employee headcount for Immunex is disclosed
2002-09-30divestiture_reductioncompleted2002-05-312002-07-17GlobalLeukine businessbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Immunex Leukine assets to Schering AG Germany for approximately $389.9 million cash plus milestones; no employee count disclosed
2002-09-30restructuringin_progress2002-07-15United StatesCompany-wide (Immunex integration: personnel, R&D programs, facilities)USD 49 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Integration plan covering terminations/relocations of certain Immunex personnel, termination of duplicative Immunex R&D programs, and consolidation of leased facilities; approximately $48.7 million accrued at close, of which about $19.3 million remained unpaid at September 30, 2002; no employee count disclosed and plans for other aspects not yet finalized
2002-09-30acquisition_additioncompleted2002-07-15business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Immunex completed July 15, 2002. Headcount added not explicitly quantified in the filing.
2002-09-30restructuringin_progress2002-07-15USD 49 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Integration plan initiated post-acquisition including termination and relocation of certain Immunex personnel. $48.7 million provided for employee terminations and relocations; employee count not explicitly disclosed.
2002-06-30acquisition_additioncompleted2001-12-162002-07-15United StatesImmunex CorporationUSD 17,700 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Immunex acquisition completed July 15, 2002; total value approximately $17.7 billion including transaction fees. Immunex employees became Amgen employees but no headcount figure is disclosed. Approximately 22.4 million Immunex stock options were assumed on a converted basis.
2002-06-30divestiture_reductioncompleted2002-05-022002-07-31United StatesLeukine (sargramostim) businessUSD 380 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Immunex agreed in May 2002 to sell its Leukine business to Schering AG Germany for approximately $380 million cash plus milestone consideration; sale completed in July 2002 after the Immunex acquisition closed. No employee count disclosed.
2002-06-30acquisition_additioncompleted2001-12-172002-07-15United StatesAllsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Amgen completed the Immunex merger on 2002-07-15, issuing ~244.6M shares and paying ~$2.5B cash; total acquisition value ~$17.7B. No employee headcount added is disclosed.
2002-06-30divestiture_reductioncompleted2002-05-022002-07-31GlobalLeukine (sargramostim) businesssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Immunex agreed in May 2002 to sell its Leukine business to Schering AG for ~$380M cash plus milestones; sale completed July 2002 after Immunex acquisition close. No employee count disclosed.
2002-03-31acquisition_additionannounced2001-12-162002-06-30USD 18 (billions)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Definitive agreement to acquire Immunex Corporation; each Immunex share to be converted into 0.44 Amgen shares plus $4.50 cash; estimated purchase price approximately $17.7 billion including cash portion of about $2.5 billion; expected to close as early as June 2002 subject to shareholder and regulatory approvals. No headcount figures disclosed.
2001-12-31acquisition_additionannounced2001-12-162002business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Definitive agreement signed December 16, 2001 to acquire Immunex Corporation for an estimated purchase price of approximately $17.6 billion; each Immunex share to be converted into 0.44 Amgen shares plus $4.50 cash. Expected to close in the second half of 2002, subject to shareholder and regulatory approvals. No acquired or combined employee headcount figures are disclosed. Also described in Item 1 (Business) and Item 7 (MD&A); in connection with the merger, Immunex intends to divest its LEUKINE product. Included here as the filing's principal workforce-affecting event; action captured as announced only since the transaction had not closed as of fiscal year-end.
2001-12-31acquisition_additionannounced2001-12-162002-12-31United StatesAllother
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement signed December 16, 2001 to acquire Immunex Corporation; estimated purchase price approximately $17.6 billion; expected to close second half of 2002; no employee count disclosed for Immunex
2000-12-31acquisition_additioncompleted2000-10-162000-12-14Research and development — small molecule kinase inhibitor drug discoveryUSD 7 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Headcount added through the acquisition was not disclosed. Amgen acquired all outstanding Kinetix shares in a tax-free exchange for 2.6 million Amgen shares, valuing the deal at $172.2 million; $6.5 million of restricted Amgen stock was issued for Kinetix restricted stock held by employees retained from Kinetix, to be recognized as compensation expense over the vesting period. Merger agreement dated October 16, 2000; acquisition completed December 14, 2000.
2000-12-31acquisition_additioncompleted2000-12-142000-12-14United StatesResearch and developmentUSD 30 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Kinetix Pharmaceuticals completed Dec 14, 2000; headcount added not disclosed. $30.1M write-off of acquired in-process R&D recorded.
2000-09-30acquisition_additionannounced402000-10-162000-12-31United StatesSmall molecule drug discovery (protein kinase inhibition)USD 30 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Agreement to acquire privately held Kinetix Pharmaceuticals for approximately $170 million in stock; company has approximately 40 employees. Expected non-recurring after-tax charge of ~$30 million to write off acquired in-process R&D; deal expected to close by end of 2000, subject to Kinetix stockholder approval and regulatory conditions.
2000-09-30acquisition_additionannounced402000-10-162000-12-31Medford, Massachusetts, United StatesResearch and development (small molecule drug discovery, protein kinase inhibition)USD 30 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 40 employees; $170M all-stock tax-free acquisition of Kinetix Pharmaceuticals, Inc.; expected non-recurring after-tax charge of about $30M ($0.03/share) to write off acquired in-process R&D. Acquisition pending Kinetix stockholder approval and regulatory clearance.
2000-09-30acquisition_additionannounced402000-10-162000-12-31Medford, MassachusettsResearch and DevelopmentUSD 170 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Kinetix Pharmaceuticals, Inc. announced October 16, 2000. Kinetix has approximately 40 employees. Purchase price is approximately $170 million in stock. Expected to complete by end of 2000.
1998-12-31restructuringcompleted1998-04United States (Boulder, Colorado; Thousand Oaks, California)Research and development — inflammation programsItem_1_Business
f5-10k / GLM-5.3-flash-HTML		After seeking a corporate partner from September 1997, the company decided in April 1998 to retain its lead inflammation candidates (sTNF-RI and IL-1ra), relocate their development programs to Thousand Oaks, and discontinue the Boulder-based discovery research programs. No headcount impact or charge was quantified. Related Item 2 disclosure: in 1998 the company agreed to sell eight of its ten Boulder buildings, with six leased back for up to three years.
1998-12-31restructuringcompleted1998-04-01United States (Boulder, Colorado to Thousand Oaks, California)Inflammation research and developmentItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Announced April 1998 after a six-month search for a corporate partner for the Boulder inflammation R&D programs; no employee count or charge disclosed